busulfan has been researched along with Leucocythaemia in 436 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The preparative therapy consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for graft-versus-host disease (GVHD) prophylaxis." | 9.11 | Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. ( Brochstein, JA; Carter, SL; Frangoul, H; Goyal, RK; Horan, JT; Kamani, NR; Kapoor, N; Kernan, NA; Kurtzberg, J; Pietryga, D; Wagner, JE; Wall, DA, 2005) |
| "Decitabine is a hypomethylating agent that has activity in patients with leukemia." | 9.10 | Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. ( Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003) |
| "This study compares maximal daily doses of loperamide to escalating doses of continuous intravenous (CI) octreotide acetate in bone marrow transplant (BMT) and leukemia patients." | 9.08 | Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. ( Davidson, TG; Dix, SP; Geller, RB; Gilmore, CE; Holland, HK; Lin, LS; Topping, DL; Wingard, JR, 1995) |
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 9.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 9.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 9.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML)." | 9.06 | Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. ( Copelan, EA; Klein, JP; Tutschka, PJ, 1987) |
| "Cyclophosphamide plus total body irradiation (CYTBI) and oral busulfan plus cyclophosphamide (BUCY) are commonly used conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with leukemia." | 8.87 | Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. ( Dantkale, V; Gupta, T; Kannan, S; Laskar, S, 2011) |
| " We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen." | 7.96 | Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec ( Balduzzi, A; Calore, E; Fagioli, F; Faraci, M; Favre, C; Giorgiani, G; Locatelli, F; Pagliara, D; Prete, A; Quarello, P; Saglio, F; Tambaro, FP; Zecca, M, 2020) |
| "We describe the case of a 16-month-old girl with neuroblastoma and chronic lymphocytopenia due to chemotherapy and treosulfan-containing megatherapy who developed cytomegalovirus retinitis and neuritis." | 7.81 | Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant. ( Bilska, K; Prost, M; Raciborska, A; Rodriguez-Galindo, C; Rychlowska-Pruszynska, M; Ussowicz, M, 2015) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 7.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 7.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| "We retrospectively compared morbidity and non-relapse mortality (NRM) after allogeneic bone marrow transplantation (BMT) in 236 adults with leukemia and myelodysplastic syndrome conditioned with cyclophosphamide plus oral versus intravenous busulfan." | 7.73 | Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. ( Choi, SJ; Kim, SE; Lee, JH; Lee, KH; Ryu, SG, 2005) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma." | 7.66 | Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). ( Ernst, P; Ersbøl, J; Hou-Jensen, K; Knudtzon, S; Larsen, MS; Nissen, NI; Pedersen-Bjergaard, J; Rose, C; Sørensen, HM, 1980) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 7.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 6.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| " The responses and adverse events of the 2 groups were assessed." | 5.34 | [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]. ( Li, J; Luo, SK; Peng, AH; Tong, XZ; Xu, DR; Zhang, GC; Zheng, D; Zou, WY, 2007) |
| " The preparative therapy consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for graft-versus-host disease (GVHD) prophylaxis." | 5.11 | Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. ( Brochstein, JA; Carter, SL; Frangoul, H; Goyal, RK; Horan, JT; Kamani, NR; Kapoor, N; Kernan, NA; Kurtzberg, J; Pietryga, D; Wagner, JE; Wall, DA, 2005) |
| "Decitabine is a hypomethylating agent that has activity in patients with leukemia." | 5.10 | Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. ( Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K, 2003) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "This study compares maximal daily doses of loperamide to escalating doses of continuous intravenous (CI) octreotide acetate in bone marrow transplant (BMT) and leukemia patients." | 5.08 | Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. ( Davidson, TG; Dix, SP; Geller, RB; Gilmore, CE; Holland, HK; Lin, LS; Topping, DL; Wingard, JR, 1995) |
| "The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation." | 5.07 | Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992) |
| "In both animal models and human studies in leukemia, residual disease on day 8 following myelosuppressive therapy is in a proliferative phase and therefore may be sensitive to the S-phase specific drug cytarabine." | 5.07 | Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. ( Chandler, C; Devine, S; Geller, RB; Larson, RA; Myers, S; O'Toole, K; Park, CL; Topper, RL; Williams, SF, 1992) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 5.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 5.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| "Sixteen patients with poor-prognosis acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL) underwent conditioning with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BUCY-2) plus melphalan (90 or 135 mg/m2) and autologous bone marrow transplantation (AuBMT) in a phase I study." | 5.07 | Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. ( Barnett, MJ; Chan, KW; Klingemann, HG; Lansdorp, PM; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ, 1991) |
| "Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML)." | 5.06 | Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. ( Copelan, EA; Klein, JP; Tutschka, PJ, 1987) |
| "Cyclophosphamide plus total body irradiation (CYTBI) and oral busulfan plus cyclophosphamide (BUCY) are commonly used conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with leukemia." | 4.87 | Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. ( Dantkale, V; Gupta, T; Kannan, S; Laskar, S, 2011) |
| "Myeloablative conditioning regimens decrease the risk of relapse in pediatric patients undergoing allogeneic hematopoietic stem cell transplant (HCT) for hematologic malignancies, but cause significant toxicities PROCEDURE: This prospective study evaluated the use of a reduced-toxicity, myeloablative regimen with dose-adjusted busulfan, fludarabine, antithymocyte globulin and 400 cGy of total body irradiation in 40 patients < 21 years of age undergoing HCT for high-risk leukemias." | 4.02 | Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ( Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT, 2021) |
| " We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen." | 3.96 | Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec ( Balduzzi, A; Calore, E; Fagioli, F; Faraci, M; Favre, C; Giorgiani, G; Locatelli, F; Pagliara, D; Prete, A; Quarello, P; Saglio, F; Tambaro, FP; Zecca, M, 2020) |
| "Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration-time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia." | 3.85 | HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. ( Aoki, Y; Fujimura, J; Hoshino, A; Imai, K; Ishiwata, Y; Kajiwara, M; Kanegane, H; Mae, T; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Mizutani, S; Morio, T; Nishimura, A; Takagi, M; Takikawa, K; Tanaka, M; Tomita, O; Tomizawa, D; Yanagimachi, M; Yasuhara, M, 2017) |
| "To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010." | 3.83 | European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. ( Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M, 2016) |
| "We describe the case of a 16-month-old girl with neuroblastoma and chronic lymphocytopenia due to chemotherapy and treosulfan-containing megatherapy who developed cytomegalovirus retinitis and neuritis." | 3.81 | Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant. ( Bilska, K; Prost, M; Raciborska, A; Rodriguez-Galindo, C; Rychlowska-Pruszynska, M; Ussowicz, M, 2015) |
| " The records of 71 patients diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), or myelodysplastic leukemia (MDS) who had undergone allogeneic HSCT with a conditioning regimen of busulfan-cyclophosphamide (Bu-Cy), between September 2003 and January 2009 at the Stem Cell Transplantation Unit of Gazi University Hospital were retrospectively evaluated." | 3.78 | The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. ( Akı, ŞZ; Altındal, Ş; Baysal, NA; Çakar, MK; Şanlıer, N; Sucak, GT; Suyanı, E; Yeğin, ZA, 2012) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 3.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "To explore the safety and efficacy of low dose heparin for the prevention of hepatic veno-occlusive disease (VOD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioned with busulfan and cyclophosphamide (BU-CY2) and the ideal time frame of the heparin administration." | 3.74 | [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation]. ( Chen, J; Chen, ST; Zeng, HL; Zhang, T; Zhong, J; Zhu, KE, 2007) |
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 3.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| "Treosulfan was more active against leukemic cells of 20 children as well as against 3 leukemia-derived cell lines than busulfan, with increasing IC50 values from initial diagnosis to relapse." | 3.74 | Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. ( Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY, 2008) |
| " As little data are available about the in-vitro toxicity of busulfan and treosulfan especially on pediatric tumor cell lines, we compared the cytotoxicity of treosulfan and busulfan on four Ewing tumor, four neuroblastoma, two osteosarcoma and two leukemia cell lines in vitro." | 3.73 | Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. ( Boos, J; Bremer, A; Dirksen, U; Jürgens, H; Lanvers-Kaminsky, C, 2006) |
| "We retrospectively compared morbidity and non-relapse mortality (NRM) after allogeneic bone marrow transplantation (BMT) in 236 adults with leukemia and myelodysplastic syndrome conditioned with cyclophosphamide plus oral versus intravenous busulfan." | 3.73 | Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. ( Choi, SJ; Kim, SE; Lee, JH; Lee, KH; Ryu, SG, 2005) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "Twelve patients with leukemia, including 4 in complete remission, whose HLAs were full matched with donors, and 8 with refractory leukemia, whose HLAs were mismatched, were transplanted with G-CSF mobilized allogeneic peripheral blood stem cells after conditioned with a regimen consisting of fludarabine (30 mg/m(2) x 6 days), busulfan (4 mg/kg x 2 days) and cyclophosphamide (30 approximately 60 mg/kg x 2 days) (FBC)." | 3.71 | [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation]. ( Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y, 2002) |
| "Using nonmyeloablative, immunosuppressive, fludarabine (FLU)-based conditioning regimens, we have performed allogeneic peripheral blood stem cell transplants in 26 patients (8 with chronic myelogenous leukemia, 6 with acute myelogenous leukemia, 10 with acute lymphoblastic leukemia, 1 with myelodysplasia, and 1 with thalassemia major)." | 3.71 | Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. ( Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "The toxic effects of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) with autologous or syngeneic bone marrow rescue were evaluated in 19 patients (11 with acute myelocytic leukemia, one with acute lymphocytic leukemia, one with acute myelofibrosis, two with chronic myelocytic leukemia, one with Hodgkin's disease, and three with non-Hodgkin's lymphoma)." | 3.67 | Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. ( Braine, HG; Kaizer, H; Lu, C; Santos, GW; Saral, R; Tutschka, PJ, 1984) |
| "Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma." | 3.66 | Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). ( Ernst, P; Ersbøl, J; Hou-Jensen, K; Knudtzon, S; Larsen, MS; Nissen, NI; Pedersen-Bjergaard, J; Rose, C; Sørensen, HM, 1980) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 3.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "A population pharmacokinetic analysis was performed in 30 patients who received an intravenous busulfan and cyclophosphamide regimen before hematopoietic stem cell transplantation." | 2.72 | Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. ( Nakashima, D; Takama, H; Takaue, Y; Tanaka, H; Ueda, R, 2006) |
| " In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen." | 2.71 | Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. ( Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004) |
| "Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =." | 2.69 | Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999) |
| "Chlorambucil and melphalan were the most leukemogenic drugs, followed by thiotepa; cyclophosphamide and treosulfan were the weakest leukemogens, and the effect per gram was substantially lower at high doses than at lower doses." | 2.67 | Leukemia following chemotherapy for ovarian cancer. ( Bell, J; Clarke, EA; Day, NE; Høst, H; Kaldor, JM; Karjalainen, S; Mehnert, W; Pedersen, D; Pettersson, F; Prior, P, 1990) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| "Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "To evaluate the toxic extramedullary morbidity of the conditioning treatment with BuCy for BMT, as well as the usefulness of pentoxyphyllin (PTX) and methylprednisolone (MP) in the prophylaxis of mucositis." | 2.39 | [Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. ( Maldonado, J; Pascual, MJ, 1995) |
| "Relapse is one of the main complications." | 2.38 | Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia. ( Devergie, A; Esperou-Bourdeau, H; Gluckman, E; Ribaud, P; Socie, G; Traineau, R, 1991) |
| "The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity." | 2.38 | High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. ( Boyd, AW; Brodie, GN; Green, MD; Griffiths, JD; McGrath, KM; Russell, DM; Scarlett, JD; Sheridan, WP; Thomas, RJ; Vaughan, SL, 1989) |
| "Chronic granulocytic leukemia, chronic lymphocytic leukemia and its variants, and hairy cell leukemia are characterized by prominent organ infiltration and marrow replacement, with a course consisting of years." | 2.36 | The chronic leukemias. ( Liepman, MK, 1980) |
| " PT was graded using Common Terminology Criteria for Adverse Events version 5." | 1.72 | Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. ( Chen, YH; Duncan, CN; Lehmann, LE; Liu, KX; Marcus, KJ; Margossian, S; Moore, N; Poux, N; Shin, KY; Whangbo, JS, 2022) |
| " The aim of this study was to derive a novel once-daily intravenous (IV) busulfan dosing nomogram for pediatric patients undergoing HSCT using a population pharmacokinetic (PK) model." | 1.46 | Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. ( Choi, JY; Hong, CR; Hong, KT; Kang, HJ; Lee, H; Lee, JW; Park, KD; Rhee, SJ; Shin, HY; Song, SH; Yu, KS, 2017) |
| "A total of 30 patients with hematologic malignancies (8 cases of AML, 17 AML, 2 MDS and 3 Mix-AL) received related haploidentical and unrelated HLA-mismatched allo-HSCT combined with related haploidentical bone marrow infusion." | 1.43 | [Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies]. ( Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ, 2016) |
| "Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs." | 1.42 | Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). ( Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L, 2015) |
| "High variability in the assessed pharmacokinetic parameters was observed, with a 38% variation in C(ss) between TD and conditioning regimen; Cl(T)/F decreased by 30%, suggesting drug accumulation after multiple-dose regimen." | 1.42 | Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization. ( Bariani, C; Carneiro, WJ; Cunha, LC; de Moraes Arantes, A; de Oliveira Neto, JR; Effting, C; Queiroz Labre, LV; Rodrigues, AR; Rodrigues, CR, 2015) |
| "Diagnoses of leukemia (n = 11), Hodgkin's lymphoma (n = 3), myelodysplastic syndrome (n = 2), and other (n = 5) were included." | 1.35 | Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. ( Ikeda, A; Kim, AH; Moore, TB; Tse, JC, 2009) |
| " The responses and adverse events of the 2 groups were assessed." | 1.34 | [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]. ( Li, J; Luo, SK; Peng, AH; Tong, XZ; Xu, DR; Zhang, GC; Zheng, D; Zou, WY, 2007) |
| "Data on 181 of 230 patients with aplastic anemia, leukemias, and lymphomas who had BMT before puberty (mean age, 9." | 1.30 | Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. ( Bakker, B; Cahn, JY; Cohen, A; Dopfer, R; Esperou, H; Gaiero, A; Kolb, HJ; Leiper, AD; Merlo, F; Rovelli, A; Socié, G; Uderzo, C; van Lint, MT, 1999) |
| " Pharmacokinetic parameters in individual patients have been related to short-term toxicity and risk of relapse after HSCT." | 1.30 | Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. ( Deeg, J; Ehninger, G; Ehrsam, M; Schmidt, H; Schneider, A; Schuler, US, 1998) |
| "Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia." | 1.29 | Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. ( Avalos, B; Bolwell, B; Copelan, E; Crilley, P; Gajewski, J; Klein, J; Sahebi, F; Territo, M, 1996) |
| " The present model is reliable and adequate for studying more patients, with a long-term follow-up combined with drug monitoring in correlation with drug efficacy and toxicity to define the optimal busulphan dosage required." | 1.29 | Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. ( Fasth, A; Gerritsen, B; Haraldsson, A; Hassan, M; Karlsson, M; Kumlien, S; Sandström, M; Syrůcková, Z; van den Berg, H; Vossen, J, 1996) |
| " Etoposide at a dose of 60-65 mg/kg in combination with TBI and cyclophosphamide was associated with a significantly increased incidence of life threatening or fatal toxicities compared with a combination using a dose of 25-50 mg/kg (15 of 24 vs." | 1.29 | Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. ( Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C, 1994) |
| " There were seven acute toxic deaths (8%) and in total 15 patients experienced life-threatening or fatal toxicity." | 1.29 | Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. ( Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D, 1995) |
| " To optimize BU dosage in young BMT recipients, we developed a dosage regimen based on body surface area (BSA) and determined BU pharmacokinetics and BU-associated toxicities." | 1.28 | Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. ( Graham, ML; Grochow, LB; Jones, RJ; Santos, GW; Wagner, JE; Yeager, AM, 1992) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 280 (64.22) | 18.7374 |
| 1990's | 70 (16.06) | 18.2507 |
| 2000's | 49 (11.24) | 29.6817 |
| 2010's | 31 (7.11) | 24.3611 |
| 2020's | 6 (1.38) | 2.80 |
| Authors | Studies |
|---|---|
| Jurkovic Mlakar, S | 1 |
| Uppugunduri, SCR | 1 |
| Nava, T | 1 |
| Mlakar, V | 1 |
| Golay, H | 1 |
| Robin, S | 1 |
| Waespe, N | 1 |
| Rezgui, MA | 1 |
| Chalandon, Y | 1 |
| Boelens, JJ | 1 |
| Bredius, RGM | 1 |
| Dalle, JH | 1 |
| Peters, C | 4 |
| Corbacioglu, S | 1 |
| Bittencourt, H | 1 |
| Krajinovic, M | 1 |
| Ansari, M | 1 |
| Wang, X | 1 |
| Mu, D | 1 |
| Geng, A | 1 |
| Zhao, A | 1 |
| Song, Y | 1 |
| Bonifazi, F | 1 |
| Pavoni, C | 1 |
| Peccatori, J | 1 |
| Giglio, F | 1 |
| Arpinati, M | 1 |
| Busca, A | 1 |
| Bernasconi, P | 1 |
| Grassi, A | 1 |
| Iori, AP | 1 |
| Patriarca, F | 1 |
| Brunello, L | 1 |
| Di Grazia, C | 1 |
| Carella, AM | 1 |
| Cilloni, D | 1 |
| Picardi, A | 1 |
| Proia, A | 1 |
| Santarone, S | 1 |
| Sorasio, R | 1 |
| Carluccio, P | 1 |
| Chiusolo, P | 1 |
| Cupri, A | 1 |
| Luppi, M | 1 |
| Nozzoli, C | 1 |
| Baronciani, D | 1 |
| Casini, M | 1 |
| Grillo, G | 1 |
| Musso, M | 1 |
| Onida, F | 1 |
| Palazzo, G | 1 |
| Parma, M | 1 |
| Tringali, S | 1 |
| Vacca, A | 1 |
| Vallisa, D | 1 |
| Sacchi, N | 1 |
| Oldani, E | 1 |
| Masciulli, A | 1 |
| Gheorghiu, A | 1 |
| Girmenia, C | 1 |
| Martino, M | 1 |
| Bruno, B | 1 |
| Rambaldi, A | 1 |
| Ciceri, F | 1 |
| Liu, KX | 1 |
| Poux, N | 1 |
| Shin, KY | 1 |
| Moore, N | 1 |
| Chen, YH | 3 |
| Margossian, S | 1 |
| Whangbo, JS | 1 |
| Duncan, CN | 1 |
| Lehmann, LE | 1 |
| Marcus, KJ | 1 |
| Saglio, F | 1 |
| Zecca, M | 2 |
| Pagliara, D | 1 |
| Giorgiani, G | 1 |
| Balduzzi, A | 1 |
| Calore, E | 1 |
| Favre, C | 1 |
| Faraci, M | 1 |
| Prete, A | 1 |
| Tambaro, FP | 1 |
| Quarello, P | 1 |
| Locatelli, F | 1 |
| Fagioli, F | 1 |
| Rossoff, J | 1 |
| Jacobsohn, D | 1 |
| Kwon, S | 1 |
| Kletzel, M | 1 |
| Duerst, RE | 1 |
| Tse, WT | 1 |
| Schneiderman, J | 1 |
| Chaudhury, S | 1 |
| Rhee, SJ | 1 |
| Lee, JW | 1 |
| Yu, KS | 1 |
| Hong, KT | 1 |
| Choi, JY | 1 |
| Hong, CR | 1 |
| Park, KD | 1 |
| Shin, HY | 1 |
| Song, SH | 1 |
| Kang, HJ | 1 |
| Lee, H | 1 |
| Gayoso, J | 1 |
| Balsalobre, P | 1 |
| Kwon, M | 1 |
| Herrera, P | 1 |
| Bermúdez, A | 1 |
| Sampol, A | 1 |
| Jiménez, S | 1 |
| López-Corral, L | 1 |
| Serrano, D | 2 |
| Piñana, JL | 1 |
| Pascual, MJ | 2 |
| Heras, I | 2 |
| Bento, L | 1 |
| Varela, R | 1 |
| Humala, K | 1 |
| Zabalza, A | 1 |
| Laiglesia, A | 1 |
| Bastos-Oreiro, M | 1 |
| Pérez-Corral, A | 1 |
| Martínez-Laperche, C | 1 |
| Buño, I | 1 |
| Díez-Martín, JL | 1 |
| Zhang, BL | 1 |
| Zhou, J | 1 |
| Lyu, TX | 1 |
| Gui, RR | 1 |
| Zu, YL | 1 |
| Yu, FK | 1 |
| Zhao, HF | 1 |
| Li, Z | 1 |
| Wang, J | 2 |
| Zhang, YL | 1 |
| Zhang, WL | 1 |
| Fu, YW | 1 |
| Wei, XD | 1 |
| Fang, BJ | 1 |
| Li, YF | 1 |
| Zhou, KS | 1 |
| Song, YP | 1 |
| Boysen, G | 1 |
| Shimoni, A | 3 |
| Danylesko, I | 2 |
| Varda-Bloom, N | 1 |
| Nagler, A | 5 |
| Nishimoto, M | 3 |
| Nakamae, H | 3 |
| Watanabe, K | 1 |
| Koh, H | 3 |
| Nakane, T | 3 |
| Ohsawa, M | 1 |
| Arakawa, T | 1 |
| Hino, M | 3 |
| Kato, M | 1 |
| Takahashi, Y | 1 |
| Tomizawa, D | 2 |
| Okamoto, Y | 1 |
| Inagaki, J | 1 |
| Koh, K | 1 |
| Ogawa, A | 1 |
| Okada, K | 1 |
| Cho, Y | 1 |
| Takita, J | 1 |
| Goto, H | 2 |
| Sakamaki, H | 2 |
| Yabe, H | 1 |
| Kawa, K | 1 |
| Suzuki, R | 1 |
| Kudo, K | 1 |
| Kato, K | 2 |
| Bredeson, C | 1 |
| Vatanen, A | 1 |
| Wilhelmsson, M | 1 |
| Borgström, B | 2 |
| Gustafsson, B | 1 |
| Taskinen, M | 1 |
| Saarinen-Pihkala, UM | 1 |
| Winiarski, J | 2 |
| Jahnukainen, K | 1 |
| Fu, H | 1 |
| Xu, L | 1 |
| Liu, D | 1 |
| Liu, K | 1 |
| Zhang, X | 1 |
| Chen, H | 2 |
| Chen, Y | 1 |
| Han, W | 2 |
| Wang, Y | 1 |
| Wang, F | 1 |
| Huang, X | 1 |
| Effting, C | 1 |
| de Moraes Arantes, A | 1 |
| Queiroz Labre, LV | 1 |
| Carneiro, WJ | 1 |
| de Oliveira Neto, JR | 1 |
| Bariani, C | 1 |
| Rodrigues, CR | 1 |
| Rodrigues, AR | 1 |
| Cunha, LC | 1 |
| Martino, R | 1 |
| Bautista, G | 1 |
| Parody, R | 1 |
| García, I | 1 |
| Esquirol, A | 1 |
| Rovira, M | 1 |
| Cabrera, JR | 1 |
| Regidor, C | 1 |
| Fores, R | 1 |
| García-Marco, JA | 1 |
| Barba, P | 1 |
| Marquez-Malaver, FJ | 1 |
| Sánchez-Ortega, I | 1 |
| Duarte, R | 1 |
| Saavedra, S | 1 |
| Sierra, J | 2 |
| Vazquez, L | 1 |
| Katayama, T | 1 |
| Hayashi, Y | 2 |
| Nakashima, Y | 1 |
| Nakamae, M | 2 |
| Hirose, A | 2 |
| Boztug, H | 1 |
| Sykora, KW | 1 |
| Slatter, M | 1 |
| Veys, P | 1 |
| Lankester, A | 1 |
| Cant, A | 1 |
| Skinner, R | 1 |
| Wachowiak, J | 1 |
| Glogova, E | 1 |
| Pötschger, U | 1 |
| Sun, Y | 1 |
| Xiao, J | 1 |
| Li, ZH | 1 |
| Fan, SF | 1 |
| Shen, Y | 1 |
| Raciborska, A | 1 |
| Ussowicz, M | 1 |
| Prost, M | 1 |
| Bilska, K | 1 |
| Rodriguez-Galindo, C | 1 |
| Rychlowska-Pruszynska, M | 1 |
| Li, WD | 1 |
| Gao, ZY | 2 |
| Yu, XJ | 1 |
| Lu, DY | 1 |
| Lu, DP | 2 |
| Takagi, M | 1 |
| Ishiwata, Y | 1 |
| Aoki, Y | 1 |
| Miyamoto, S | 1 |
| Hoshino, A | 1 |
| Matsumoto, K | 1 |
| Nishimura, A | 1 |
| Tanaka, M | 1 |
| Yanagimachi, M | 1 |
| Mitsuiki, N | 1 |
| Imai, K | 1 |
| Kanegane, H | 1 |
| Kajiwara, M | 1 |
| Takikawa, K | 1 |
| Mae, T | 1 |
| Tomita, O | 1 |
| Fujimura, J | 1 |
| Yasuhara, M | 1 |
| Mizutani, S | 2 |
| Morio, T | 1 |
| Kim, AH | 1 |
| Tse, JC | 1 |
| Ikeda, A | 1 |
| Moore, TB | 1 |
| Kerbauy, FR | 1 |
| Tirapelli, B | 1 |
| Akabane, H | 1 |
| Oliveira, JS | 1 |
| Li, QB | 1 |
| Li, L | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Xia, LH | 1 |
| Zou, P | 1 |
| Yamamoto, M | 1 |
| Kuroda, J | 1 |
| Uchiyama, H | 1 |
| Kobayashi, T | 1 |
| Tsutsumi, Y | 1 |
| Ohshiro, M | 1 |
| Sasaki, N | 1 |
| Shimura, Y | 1 |
| Matsumoto, Y | 1 |
| Shimazaki, C | 2 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Shi-Xia, X | 1 |
| Xian-Hua, T | 1 |
| Hai-Qin, X | 1 |
| Bo, F | 1 |
| Xiang-Feng, T | 1 |
| Terada, Y | 1 |
| Aimoto, R | 1 |
| Inoue, E | 1 |
| Yoshimura, T | 1 |
| Inoue, A | 1 |
| Koh, KR | 1 |
| Yamane, T | 1 |
| Stein, AS | 1 |
| O'Donnell, MR | 1 |
| Synold, TW | 1 |
| Dagis, AC | 1 |
| Tsirunyan, A | 1 |
| Nademanee, AP | 1 |
| Parker, PM | 1 |
| Pullarkat, VA | 1 |
| Snyder, DS | 1 |
| Spielberger, RT | 1 |
| Wong, JY | 1 |
| Alvarnas, JC | 1 |
| Thomas, SH | 1 |
| Forman, SJ | 2 |
| GRIFONI, V | 1 |
| Gupta, T | 1 |
| Kannan, S | 1 |
| Dantkale, V | 1 |
| Laskar, S | 1 |
| Wong, AM | 1 |
| Allen, JC | 1 |
| Goh, YT | 1 |
| Linn, YC | 1 |
| Loh, SM | 1 |
| Diong, CP | 1 |
| Chowbay, B | 1 |
| Hwang, WY | 1 |
| Gupta, A | 1 |
| Le, A | 1 |
| Belinka, BA | 1 |
| Kachlany, SC | 1 |
| Lee, KH | 4 |
| Lee, JH | 8 |
| Kim, DY | 2 |
| Seol, M | 2 |
| Lee, YS | 1 |
| Kang, YA | 1 |
| Jeon, M | 1 |
| Hwang, HJ | 1 |
| Jung, AR | 1 |
| Kim, SH | 1 |
| Yun, SC | 1 |
| Shin, HJ | 2 |
| Magenau, J | 1 |
| Tobai, H | 1 |
| Pawarode, A | 1 |
| Braun, T | 1 |
| Peres, E | 1 |
| Reddy, P | 2 |
| Kitko, C | 1 |
| Choi, S | 1 |
| Yanik, G | 1 |
| Frame, D | 1 |
| Harris, A | 1 |
| Erba, H | 1 |
| Kujawski, L | 1 |
| Elenitoba-Johnson, K | 1 |
| Sanks, J | 1 |
| Jones, D | 1 |
| Paczesny, S | 1 |
| Ferrara, J | 1 |
| Levine, J | 1 |
| Mineishi, S | 1 |
| Sucak, GT | 1 |
| Suyanı, E | 1 |
| Baysal, NA | 1 |
| Altındal, Ş | 1 |
| Çakar, MK | 1 |
| Akı, ŞZ | 1 |
| Yeğin, ZA | 1 |
| Şanlıer, N | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Joo, YD | 1 |
| Kim, H | 1 |
| Ryoo, HM | 1 |
| Kim, MK | 1 |
| Lee, GW | 1 |
| Lee, WS | 1 |
| Park, JH | 1 |
| Bae, SH | 1 |
| Hyun, MS | 1 |
| Kim, SD | 1 |
| Min, YJ | 1 |
| Le Bourgeois, A | 1 |
| Lestang, E | 1 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| Ayari, S | 1 |
| Blin, N | 1 |
| Clavert, A | 1 |
| Tessoulin, B | 1 |
| Dubruille, V | 1 |
| Mahe, B | 1 |
| Roland, V | 1 |
| Gastinne, T | 1 |
| Le Gouill, S | 1 |
| Moreau, P | 1 |
| Mohty, M | 1 |
| Planche, L | 1 |
| Chevallier, P | 1 |
| Wu, B | 1 |
| Guo, K | 1 |
| Song, Z | 1 |
| Yan, D | 1 |
| Yang, Y | 1 |
| Xiao, L | 1 |
| Kim, S | 1 |
| Park, CJ | 1 |
| Chi, HS | 1 |
| Kang, W | 1 |
| Kim, ST | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Ritchie, DS | 1 |
| Szer, J | 2 |
| Roberts, AW | 1 |
| Shuttleworth, P | 1 |
| Grigg, AP | 1 |
| Basara, N | 1 |
| Roemer, E | 1 |
| Kraut, L | 1 |
| Guenzelmann, S | 1 |
| Schmetzer, B | 1 |
| Kiehl, MG | 1 |
| Fauser, AA | 1 |
| de Lima, M | 1 |
| Ravandi, F | 1 |
| Shahjahan, M | 1 |
| Andersson, B | 2 |
| Couriel, D | 1 |
| Donato, M | 1 |
| Khouri, I | 1 |
| Gajewski, J | 2 |
| van Besien, K | 1 |
| Champlin, R | 1 |
| Giralt, S | 2 |
| Kantarjian, H | 1 |
| Casper, J | 3 |
| Knauf, W | 2 |
| Kiefer, T | 1 |
| Wolff, D | 1 |
| Steiner, B | 1 |
| Hammer, U | 1 |
| Wegener, R | 1 |
| Kleine, HD | 1 |
| Wilhelm, S | 1 |
| Knopp, A | 1 |
| Hartung, G | 1 |
| Dölken, G | 1 |
| Freund, M | 2 |
| Zhang, GC | 2 |
| Zheng, D | 2 |
| Guan, XX | 1 |
| Luo, SK | 2 |
| Li, J | 2 |
| Peng, AH | 2 |
| Tong, XZ | 2 |
| Lai, FZ | 1 |
| Tan, EX | 1 |
| Hong, WD | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| BOLLAG, W | 2 |
| HADDOW, A | 1 |
| TIMMIS, GM | 1 |
| GALTON, DA | 8 |
| BERNARD, J | 1 |
| DELTOUR, G | 1 |
| PETRAKIS, NL | 1 |
| BIERMAN, HR | 1 |
| KELLY, KH | 1 |
| WHITE, LP | 2 |
| SHIMKIN, MB | 1 |
| TILL, M | 3 |
| PRIBILLA, W | 1 |
| STOLLBERG, G | 1 |
| DI PIETRO, S | 1 |
| GALLICO, E | 1 |
| HAUT, A | 2 |
| ALTMAN, SJ | 1 |
| CARTWRIGHT, GE | 2 |
| WINTROBE, MM | 2 |
| BOUSSER, J | 2 |
| CHRISTOL, D | 1 |
| LOUIS, J | 1 |
| LIMARZI, LR | 1 |
| BEST, WR | 1 |
| BLACKBURN, EK | 1 |
| KING, GM | 1 |
| SWAN, HT | 1 |
| FROST, JW | 1 |
| JACKSON, CB | 1 |
| BRICHTA, G | 1 |
| HAMMERSCHMIDT, M | 1 |
| PARZER, O | 1 |
| HYMAN, GA | 1 |
| GELLHORN, A | 1 |
| SCHILLING, RF | 1 |
| MEYER, OO | 1 |
| GREIG, HB | 1 |
| IZUMI, HM | 1 |
| TEXIER, G | 2 |
| VALLAT, JN | 2 |
| JOSEPHSEN, JO | 3 |
| BEROVIC, R | 2 |
| BUGARSKI, M | 2 |
| KONECNI, J | 2 |
| BEYREDER, J | 3 |
| HERZOG, E | 3 |
| TURESSON, D | 1 |
| NELSON, MG | 2 |
| LOWRY, J | 1 |
| BOHINJEC, J | 1 |
| CASFORD, RS | 1 |
| CLOSON, J | 1 |
| CONTENT, M | 1 |
| WILDHACK, R | 1 |
| KLIMA, R | 2 |
| UNUGUR, A | 1 |
| SCHULMAN, E | 1 |
| DAMESHEK, W | 4 |
| PETRESCU, M | 1 |
| PAPAZIAN, R | 1 |
| OLARU, C | 1 |
| KANZOW, U | 1 |
| WOLFERS, H | 1 |
| HAYHOE, FG | 2 |
| KOK, D | 1 |
| WINKLER, A | 1 |
| UJHAZY, V | 1 |
| CERNY, V | 1 |
| PAWELSKI, S | 1 |
| SOBCZYNSKA-CZECHOWSKA, Z | 1 |
| LARRAIN, C | 2 |
| MEZA ARRAU, C | 1 |
| GERBER, K | 1 |
| ZUNIGA, C | 1 |
| MIKHAILOVA, NS | 1 |
| RYBKIN, IN | 1 |
| DE VRIES, SI | 1 |
| VAN ESSER, JG | 1 |
| GIGANTE, D | 1 |
| SHERMAN, JL | 1 |
| LOCKE, RV | 1 |
| CHERNOV, VA | 1 |
| PAVLOVSKAIA, NI | 1 |
| MOKEEVA, RA | 1 |
| SHAPIRO, ZA | 1 |
| TIMOSHKINA, LF | 1 |
| MUKHAMEDZIANOVA, GS | 1 |
| BELER, B | 1 |
| ERGUN, N | 1 |
| ESTEVEZ, RA | 1 |
| PUIMAN, V | 1 |
| WILTSHAW, E | 2 |
| BETHELL, FH | 1 |
| DOCTOR, VM | 2 |
| BERGSAGEL, DE | 1 |
| SHULLENBERGER, CC | 3 |
| SHERMAN, SI | 2 |
| KUZ'MIN, DS | 2 |
| ROZANOVA, LM | 2 |
| KISELEVA, AN | 2 |
| POVERGO, NS | 2 |
| VAKULENKO, AD | 3 |
| KHURGIN, MI | 1 |
| KHASANOVA, RI | 1 |
| LANGERON, L | 1 |
| CROCCEL, L | 1 |
| ROUTIER, G | 1 |
| BOYAVAL, M | 1 |
| GUREVICH, LI | 1 |
| HAMBSCH, K | 1 |
| HAMMER, O | 1 |
| ABBOTT, WS | 1 |
| HORVATH, L | 1 |
| PAOLINO, W | 1 |
| BACHI, C | 1 |
| PLATZER, S | 1 |
| RUSOVA, AI | 1 |
| XEFTERIS, E | 1 |
| MITUS, WJ | 2 |
| MEDNICOFF, IB | 1 |
| COERS, RJ | 1 |
| DIAMOND, I | 1 |
| ANDERSON, MM | 1 |
| McCREADIE, SR | 1 |
| DUCACH, G | 1 |
| GRANIC, J | 1 |
| TORIELLO, G | 1 |
| UBILLA, V | 1 |
| DURANTE, N | 1 |
| SOLOVEI, DIa | 1 |
| IAVORKOVSKII, LI | 1 |
| SVOBODA, V | 1 |
| UMEGAKI, Y | 1 |
| WATANABE, I | 1 |
| WALLER, U | 1 |
| ANTIC, M | 1 |
| RADOJEVIC, B | 1 |
| BRIDGES, JM | 1 |
| HAYES, DM | 1 |
| ECKHARDT, S | 1 |
| SELLEI, C | 1 |
| HARTAI, F | 1 |
| EHRHART, H | 2 |
| GORELOV, IZ | 1 |
| LIPKOVICH, BI | 1 |
| GRAF, F | 1 |
| TAKACSI-NAGY, L | 1 |
| HELBIG, W | 1 |
| WEISSEL, M | 1 |
| SHVEDOV, NIa | 1 |
| TOUGH, IM | 2 |
| COURT BROWN, WM | 1 |
| BAIKIE, AG | 1 |
| HARNDEN, DG | 1 |
| JACOBS, PA | 1 |
| WILLIAMS, JA | 1 |
| UPTON, AC | 2 |
| WOLFF, FF | 1 |
| SNIFFEN, EP | 1 |
| MARCHAL, G | 1 |
| BILSKI-PASQUIER, G | 1 |
| NAJEAN, Y | 2 |
| PITNEY, WR | 1 |
| POGOSIAN, AS | 1 |
| GURELI, N | 1 |
| DENHAM, SW | 1 |
| ROOT, SW | 1 |
| HARRINGTON, WJ | 1 |
| HALLORAN, MJ | 1 |
| KIRCHOFF, VG | 1 |
| REINHARD, EH | 2 |
| GROSSMAN, R | 1 |
| WHITE, B | 1 |
| HILGER, E | 1 |
| SHARMA, RS | 1 |
| WHITE, LG | 1 |
| WIELAND, S | 1 |
| WIELAND, C | 1 |
| ANGUS, HB | 1 |
| GUNZ, FW | 2 |
| KIMURA, K | 1 |
| KURITA, S | 1 |
| LEAKE, E | 1 |
| SMITH, WG | 1 |
| ELSON, LA | 1 |
| OSSIPOVSKI, B | 1 |
| SZATMARI, E | 1 |
| FEHER, T | 1 |
| EVANS, AM | 1 |
| RIEKHOF, P | 1 |
| COLEBATCH, JH | 1 |
| TAFT, LI | 1 |
| ROSS, ED | 1 |
| SETTLE, JA | 1 |
| TELFER, AB | 1 |
| CHAPTAL, J | 1 |
| JEAN, R | 1 |
| IZARN, P | 1 |
| BONNET, H | 1 |
| NAVARRO, M | 1 |
| EMBERGER, JM | 1 |
| DOCTOR, F | 1 |
| LEHOCZKY, D | 1 |
| ONESTI, P | 1 |
| WOODLIFF, HJ | 3 |
| WEBER, RE | 1 |
| HELMAN, N | 1 |
| SAMPEY, JR | 2 |
| SPASSKII, OV | 2 |
| DE BERGSAGEL, DE | 1 |
| THOMAS, JR | 1 |
| ONIDA, L | 1 |
| FOLLI, G | 1 |
| BALGOZHINA, SZ | 1 |
| DUHAMEL, G | 1 |
| MATSUOKA, M | 1 |
| NIZET, A | 1 |
| GRIZZLE, JE | 1 |
| RITZ, ND | 2 |
| PURFAR, M | 1 |
| GALLINELLI, R | 1 |
| BARBIERI, U | 1 |
| CHITHAM, RG | 1 |
| MCIVER, EJ | 1 |
| FROMMEYER, WB | 1 |
| BOOTSMA, BK | 1 |
| LOPESCARDOZO, E | 1 |
| LAAKSO, WB | 1 |
| PLAUCHU, M | 1 |
| BERTRAND, JL | 1 |
| BANSILLON, V | 1 |
| DELAYE, J | 1 |
| MARSH, JC | 1 |
| PERRY, S | 1 |
| INAI, S | 1 |
| FUJIKAWA, K | 1 |
| MASAOKA, T | 2 |
| TAKAHASHI, H | 3 |
| NAGAKI, K | 1 |
| BALGOZHINA, ShZh | 2 |
| HAMPEL, KE | 2 |
| GERHARTZ, H | 2 |
| CHORIN, VA | 1 |
| ROSSOLIMO, OK | 1 |
| GOLDBERG, LE | 1 |
| STANISLAVSKAYA, MS | 1 |
| BLUMBERG, NA | 1 |
| VERTOGRADOVA, TP | 1 |
| COURTBROWN, WM | 1 |
| GHOSE, S | 1 |
| CHOWDHURY, AB | 1 |
| RAY, RN | 1 |
| CHATTERJEA, JB | 1 |
| KYLE, RA | 2 |
| CALERO, C | 1 |
| ORIGENES, ML | 1 |
| BEATTY, EC | 1 |
| BRUBAKER, C | 1 |
| HAMMOND, D | 1 |
| HARTMANN, JR | 1 |
| SHORE, N | 1 |
| WILLIAMS, KO | 1 |
| MOLANDER, DW | 1 |
| LADUE, JS | 1 |
| WAKISAKA, G | 1 |
| UCHINO, H | 1 |
| NAKAMURA, T | 2 |
| SHIRAKAWA, S | 2 |
| ADACHI, A | 1 |
| SAKURAI, M | 1 |
| MIYAMOTO, K | 1 |
| MURTHY, BG | 1 |
| SWISHER, SN | 1 |
| TROUP, SB | 1 |
| COWLING, DC | 1 |
| QUAGLINO, D | 1 |
| HUTCHISON, JL | 1 |
| JUNG, F | 1 |
| BLATNIK, D | 1 |
| JUNG, M | 1 |
| NICOLAU, CT | 1 |
| POPESCU, ER | 1 |
| NICOARA, ST | 1 |
| WECHSLER, B | 1 |
| BUTOIANU, E | 1 |
| TAIGAR, S | 1 |
| VERMONT, I | 1 |
| EUGENIU, A | 1 |
| GIORGIU, T | 1 |
| PEDERSEN, B | 1 |
| VIDEBAEK, A | 2 |
| KUWABARA, T | 1 |
| NELSON, BM | 1 |
| ANDREWS, GA | 1 |
| INNES, J | 1 |
| SCOTT, RB | 1 |
| ELLISON, RR | 1 |
| LEY, AB | 1 |
| MARTINEZ MALDONADO, M | 1 |
| MENENDEZ CORRADA, R | 1 |
| RIVERADESALA, A | 1 |
| BANERJEA, JC | 1 |
| MUKHERJEE, SK | 1 |
| HARDISTY, RM | 1 |
| SPEED, DE | 2 |
| KAUER, GL | 1 |
| ENGLE, RL | 1 |
| LOEB, V | 1 |
| DOUGAN, L | 1 |
| LEVITSKAIA, SV | 1 |
| BORODULINA, VI | 1 |
| CONKLIN, JW | 1 |
| CHRISTENBERRY, KW | 1 |
| TALVALKAR, GV | 1 |
| BOUNAMEAUX, Y | 1 |
| DURENNE, JM | 1 |
| MOESCHLIN, S | 2 |
| HARRAP, KR | 1 |
| DENNIS, LH | 1 |
| STEIN, S | 1 |
| GALLAGHER, TF | 1 |
| HELLMAN, L | 1 |
| ZUMOFF, B | 1 |
| MILLER, DG | 1 |
| MORROW, LB | 1 |
| ANDERSON, RE | 1 |
| PETERS, RL | 1 |
| EARLL, JM | 1 |
| MAY, RL | 1 |
| HUNSTEIN, W | 2 |
| HARWERTH, HG | 1 |
| RAJU, S | 1 |
| LINQUETTE, M | 1 |
| MESMACQUE, R | 1 |
| FOSSATI, P | 1 |
| GASNAULT, JP | 1 |
| MARSDEN, HB | 1 |
| STEWARD, JK | 1 |
| RAMIOUL, H | 2 |
| SUAREZ, RM | 2 |
| SABATER, J | 1 |
| BUSO, R | 1 |
| KURRLE, GR | 1 |
| MOROZOVA, VT | 1 |
| PEST, R | 1 |
| KRIM, M | 1 |
| LIVSHITS, RA | 1 |
| RUIZ REYES, G | 1 |
| TAMAYO PEREZ, R | 1 |
| Tamaki, H | 1 |
| Ikegame, K | 1 |
| Kawakami, M | 1 |
| Fujioka, T | 1 |
| Tsuboi, A | 1 |
| Oji, Y | 1 |
| Oka, Y | 1 |
| Sugiyama, H | 1 |
| Kawase, I | 1 |
| Ogawa, H | 1 |
| Blau, I | 1 |
| Ruutu, T | 4 |
| Volin, L | 4 |
| Wandt, H | 1 |
| Schafer-Eckart, K | 1 |
| Holowiecki, J | 1 |
| Giebel, S | 1 |
| Aschan, J | 2 |
| Zander, A | 1 |
| Kroger, N | 1 |
| Doelken, G | 1 |
| Lähteenmäki, PM | 1 |
| Chakrabarti, S | 1 |
| Cornish, JM | 1 |
| Oakhill, AH | 1 |
| Hilger, RA | 1 |
| Baumgart, J | 1 |
| Scheulen, ME | 1 |
| Trenschel, R | 1 |
| Strumberg, D | 1 |
| Seeber, S | 1 |
| Beelen, DW | 1 |
| Kim, SE | 1 |
| Choi, SJ | 1 |
| Ryu, SG | 1 |
| Wall, DA | 1 |
| Carter, SL | 1 |
| Kernan, NA | 1 |
| Kapoor, N | 4 |
| Kamani, NR | 1 |
| Brochstein, JA | 1 |
| Frangoul, H | 1 |
| Goyal, RK | 1 |
| Horan, JT | 1 |
| Pietryga, D | 2 |
| Wagner, JE | 2 |
| Kurtzberg, J | 1 |
| Garban, F | 1 |
| Drillat, P | 1 |
| Makowski, C | 1 |
| Jacob, MC | 1 |
| Richard, MJ | 1 |
| Favrot, M | 1 |
| Sotto, JJ | 1 |
| Bensa, JC | 1 |
| Cahn, JY | 2 |
| Kanda, Y | 1 |
| Sao, H | 1 |
| Okamoto, S | 1 |
| Kodera, Y | 1 |
| Tanosaki, R | 1 |
| Kasai, M | 1 |
| Hiraoka, A | 1 |
| Takahashi, S | 1 |
| Miyawaki, S | 1 |
| Kawase, T | 1 |
| Morishima, Y | 1 |
| Kato, S | 1 |
| Dong, L | 1 |
| Wu, T | 1 |
| Huang, XJ | 1 |
| Zhang, MJ | 1 |
| Liu, DH | 1 |
| Xu, LP | 1 |
| Zhang, YC | 1 |
| Ren, HY | 1 |
| Li, D | 1 |
| Liu, KY | 1 |
| Takama, H | 1 |
| Tanaka, H | 1 |
| Nakashima, D | 1 |
| Ueda, R | 1 |
| Takaue, Y | 1 |
| Lanvers-Kaminsky, C | 1 |
| Bremer, A | 1 |
| Dirksen, U | 1 |
| Jürgens, H | 1 |
| Boos, J | 1 |
| Duraj, J | 1 |
| Bodo, J | 1 |
| Sulikova, M | 1 |
| Rauko, P | 1 |
| Sedlak, J | 1 |
| Chen, J | 2 |
| Zhu, KE | 2 |
| Zhang, T | 2 |
| Zhong, J | 2 |
| Chen, ST | 1 |
| Zeng, HL | 1 |
| Li, JP | 1 |
| Iravani, M | 1 |
| Evazi, MR | 1 |
| Mousavi, SA | 1 |
| Shamshiri, AR | 1 |
| Tavakoli, M | 1 |
| Ashouri, A | 1 |
| Samiee, S | 1 |
| Chahardovali, B | 1 |
| Alimoghaddam, K | 1 |
| Ghaffari, SH | 1 |
| Ghavamzadeh, A | 1 |
| Chae, YS | 1 |
| Sohn, SK | 1 |
| Kim, JG | 1 |
| Cho, YY | 1 |
| Moon, JH | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Yang, DH | 1 |
| Lee, JJ | 1 |
| Kim, YK | 1 |
| Kim, HJ | 1 |
| Hardan, I | 1 |
| Shem-Tov, N | 1 |
| Rand, A | 1 |
| Herscovici, C | 1 |
| Yerushalmi, R | 1 |
| Xu, DR | 1 |
| Zou, WY | 1 |
| Izaki, S | 1 |
| Okuda, K | 1 |
| Matsuda, M | 1 |
| Watanabe, Y | 1 |
| Fujioka, K | 2 |
| Hanzawa, N | 1 |
| Sumita, H | 2 |
| Goto, S | 1 |
| Kai, S | 2 |
| Sekiguchi, H | 2 |
| Funabiki, T | 2 |
| Sasaki, H | 1 |
| Ikuta, K | 2 |
| Yokota, S | 1 |
| Mellgren, K | 1 |
| Nilsson, C | 1 |
| Fasth, A | 2 |
| Abrahamsson, J | 1 |
| Ringdén, O | 7 |
| Hassan, M | 4 |
| Munkelt, D | 1 |
| Koehl, U | 1 |
| Kloess, S | 1 |
| Zimmermann, SY | 1 |
| Kalaäoui, RE | 1 |
| Wehner, S | 1 |
| Schwabe, D | 1 |
| Lehrnbecher, T | 1 |
| Schubert, R | 1 |
| Kreuter, J | 1 |
| Klingebiel, T | 1 |
| Esser, R | 1 |
| Chunduri, S | 1 |
| Dobogai, LC | 1 |
| Peace, D | 1 |
| Saunthararajah, Y | 1 |
| Quigley, J | 1 |
| Mahmud, N | 1 |
| Hurter, E | 1 |
| Beri, R | 1 |
| Rondelli, D | 1 |
| Dugdale, M | 1 |
| Fort, AT | 1 |
| Hidvégi, EJ | 1 |
| Lónai, P | 1 |
| Holland, J | 1 |
| Antoni, F | 1 |
| Institoris, L | 1 |
| Horváth, IP | 1 |
| Beschorner, WE | 2 |
| Pino, J | 1 |
| Boitnott, JK | 1 |
| Tutschka, PJ | 10 |
| Santos, GW | 9 |
| Brookmeyer, R | 1 |
| Saral, R | 3 |
| Bias, WB | 1 |
| Braine, HG | 3 |
| Burns, WH | 2 |
| Elfenbein, GJ | 2 |
| Kaizer, H | 4 |
| Rappeport, JM | 1 |
| Zwaan, FE | 1 |
| Jansen, J | 1 |
| Lu, C | 1 |
| Nagao, T | 1 |
| Yamauchi, K | 1 |
| Komatsuda, M | 1 |
| Pino y Torres, JL | 1 |
| Bross, DS | 1 |
| Lam, WC | 1 |
| Wharam, MD | 1 |
| Order, SE | 1 |
| Thomas, ED | 1 |
| Liepman, MK | 1 |
| Brodsky, I | 2 |
| Pedersen-Bjergaard, J | 2 |
| Nissen, NI | 2 |
| Sørensen, HM | 2 |
| Hou-Jensen, K | 1 |
| Larsen, MS | 2 |
| Ernst, P | 1 |
| Ersbøl, J | 1 |
| Knudtzon, S | 1 |
| Rose, C | 1 |
| Geller, RB | 2 |
| Gilmore, CE | 1 |
| Dix, SP | 1 |
| Lin, LS | 1 |
| Topping, DL | 1 |
| Davidson, TG | 1 |
| Holland, HK | 1 |
| Wingard, JR | 1 |
| Maldonado, J | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Goldstone, AH | 1 |
| Newland, AC | 1 |
| Crilley, P | 2 |
| Topolsky, D | 1 |
| Styler, MJ | 1 |
| Bernstein, E | 1 |
| Resnick, K | 1 |
| Mullaney, R | 1 |
| Bulova, S | 1 |
| Marks, DI | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Baxter-Lowe, LA | 1 |
| Bunin, N | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Garbrecht, F | 1 |
| Przepiorka, D | 1 |
| Ippoliti, C | 1 |
| van Beisen, K | 1 |
| Mehra, R | 1 |
| Deisseroth, AB | 1 |
| Luna, M | 1 |
| Cork, A | 1 |
| Lee, M | 1 |
| Shank, B | 1 |
| Klaesson, S | 2 |
| Ljungman, P | 5 |
| Lönnqvist, B | 1 |
| Wennberg, L | 1 |
| Remberger, M | 4 |
| Nikoskelainen, J | 3 |
| Vindeløv, L | 3 |
| Parkkali, T | 3 |
| Lenhoff, S | 3 |
| Sallerfors, B | 3 |
| Bandini, G | 1 |
| Belardinelli, A | 1 |
| Rosti, G | 1 |
| Calori, E | 1 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Benini, C | 1 |
| Tura, S | 2 |
| Mehta, J | 1 |
| Powles, RL | 2 |
| Mitchell, P | 1 |
| Rege, K | 1 |
| De Lord, C | 1 |
| Treleaven, J | 2 |
| Kajigaya, Y | 1 |
| Sakai, H | 1 |
| Matsuyama, S | 1 |
| Spitzer, TR | 2 |
| Ortlieb, M | 1 |
| Tefft, MC | 1 |
| Torrisi, J | 2 |
| Cahill, R | 2 |
| Gadner, H | 2 |
| Urban, C | 1 |
| Deeg, HJ | 5 |
| Oberg, G | 2 |
| Björkholm, M | 1 |
| Wallin, I | 1 |
| Lindgren, M | 1 |
| Vowels, M | 1 |
| Chan, LL | 1 |
| Giri, N | 1 |
| Russell, S | 1 |
| Lam-Po-Tang, R | 1 |
| Blume, KG | 1 |
| Kopecky, KJ | 1 |
| Henslee-Downey, JP | 1 |
| Stiff, PJ | 1 |
| LeMaistre, CF | 1 |
| Appelbaum, FR | 6 |
| Inoue, T | 1 |
| Ikeda, H | 1 |
| Yamazaki, H | 1 |
| Tang, JT | 1 |
| Song, C | 1 |
| Teshima, T | 1 |
| Murayama, S | 1 |
| Ohtani, M | 1 |
| Shibata, H | 1 |
| van Tol, MJ | 1 |
| Gerritsen, EJ | 1 |
| de Lange, GG | 1 |
| van Leeuwen, AM | 1 |
| Jol-van der Zijde, CM | 1 |
| Oudeman-Gruber, NJ | 1 |
| de Vries, E | 1 |
| Radl, J | 1 |
| Vossen, JM | 1 |
| Slattery, JT | 2 |
| Kalhorn, TF | 1 |
| McDonald, GB | 1 |
| Lambert, K | 1 |
| Buckner, CD | 5 |
| Bensinger, WI | 2 |
| Anasetti, C | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Rosenfeld, CS | 1 |
| Bolwell, B | 2 |
| LeFever, A | 1 |
| Taylor, R | 1 |
| List, A | 1 |
| Fay, J | 1 |
| Collins, R | 1 |
| Andrews, F | 1 |
| Pallansch, P | 1 |
| Schuster, MW | 1 |
| Resta, D | 1 |
| Levitt, D | 1 |
| Nemunaitis, J | 1 |
| Labopin, M | 2 |
| Arcese, W | 2 |
| Iriondo, A | 1 |
| Zittoun, R | 1 |
| Gorin, NC | 1 |
| deMagalhaes-Silverman, M | 1 |
| Bloom, EJ | 1 |
| Donnenberg, A | 1 |
| Lister, J | 1 |
| Pincus, S | 1 |
| Rybka, WB | 1 |
| Ball, ED | 1 |
| Schmitz, N | 1 |
| Bacigalupo, A | 1 |
| Majolino, I | 1 |
| Laporte, JP | 1 |
| Brinch, L | 1 |
| Cook, G | 1 |
| Lambertenghi-Deliliers, G | 1 |
| Lange, A | 1 |
| Rozman, C | 1 |
| Garcia-Conde, J | 1 |
| Finke, J | 2 |
| Domingo-Albos, A | 1 |
| Gratwohl, A | 1 |
| Klein, JL | 1 |
| Avalos, BR | 4 |
| Belt, P | 1 |
| Taylor, CA | 1 |
| Ezzone, SA | 3 |
| Scholl, MD | 3 |
| Fisher, J | 1 |
| Young, D | 1 |
| Copelan, EA | 9 |
| Sahebi, F | 1 |
| Copelan, E | 1 |
| Avalos, B | 1 |
| Klein, J | 2 |
| Territo, M | 1 |
| Arslan, O | 1 |
| Akan, H | 1 |
| Koç, H | 1 |
| Beksaç, M | 1 |
| Ilhan, O | 1 |
| Ozcan, M | 1 |
| Yalçín, S | 1 |
| Gürman, G | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Tesselaar, ME | 1 |
| Wijermans, PW | 1 |
| Metsaars, JA | 1 |
| Gerrits, WB | 1 |
| Haak, HL | 1 |
| Gerritsen, B | 1 |
| Haraldsson, A | 1 |
| Syrůcková, Z | 1 |
| van den Berg, H | 1 |
| Sandström, M | 1 |
| Karlsson, M | 1 |
| Kumlien, S | 1 |
| Vossen, J | 1 |
| Penza, SL | 2 |
| Elder, PJ | 2 |
| Belt, PS | 2 |
| Hehmeyer, DM | 1 |
| Bechtel, TP | 2 |
| Barbui, T | 2 |
| Finazzi, G | 2 |
| Dupuy, E | 1 |
| Kiladjian, JJ | 1 |
| Brière, J | 1 |
| Al-Fiar, FZ | 1 |
| Colwill, R | 1 |
| Lipton, JH | 1 |
| Fyles, G | 1 |
| Spaner, D | 1 |
| Messner, H | 1 |
| Bertz, H | 1 |
| Potthoff, K | 1 |
| Mertelsmann, R | 1 |
| Békássy, AN | 1 |
| Yen, CC | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fang, FS | 1 |
| Wang, WS | 1 |
| Tung, SL | 1 |
| Tzeng, CH | 1 |
| Chen, PM | 1 |
| Schuler, US | 2 |
| Ehrsam, M | 1 |
| Schneider, A | 1 |
| Schmidt, H | 1 |
| Deeg, J | 1 |
| Ehninger, G | 2 |
| Kondo, M | 1 |
| Kojima, S | 1 |
| Matsuyama, T | 1 |
| Leahey, AM | 1 |
| Friedman, DL | 1 |
| Bunin, NJ | 1 |
| Mellander, L | 1 |
| Jacobsen, N | 1 |
| Wattel, E | 1 |
| Solary, E | 1 |
| Leleu, X | 1 |
| Dreyfus, F | 1 |
| Brion, A | 1 |
| Jouet, JP | 1 |
| Hoang-Ngoc, L | 1 |
| Maloisel, F | 1 |
| Guerci, A | 1 |
| Rochant, H | 1 |
| Gratecos, N | 1 |
| Casassus, P | 1 |
| Janvier, M | 1 |
| Brice, P | 1 |
| Lepelley, P | 1 |
| Fenaux, P | 1 |
| Cohen, A | 1 |
| Rovelli, A | 1 |
| Bakker, B | 1 |
| Uderzo, C | 1 |
| van Lint, MT | 1 |
| Esperou, H | 1 |
| Gaiero, A | 1 |
| Leiper, AD | 1 |
| Dopfer, R | 1 |
| Merlo, F | 1 |
| Kolb, HJ | 1 |
| Socié, G | 2 |
| Rosales, F | 1 |
| Naparstek, E | 2 |
| Varadi, G | 2 |
| Or, R | 2 |
| Slavin, S | 2 |
| Corvò, R | 1 |
| Carlens, S | 1 |
| Hägglund, H | 1 |
| Mattsson, J | 1 |
| Hatta, Y | 1 |
| Itoh, T | 1 |
| Baba, M | 1 |
| Shimojima, H | 1 |
| Miyajima, T | 1 |
| Izumi, T | 1 |
| Horikoshi, A | 1 |
| Takeuchi, J | 1 |
| Sawada, U | 1 |
| Horie, T | 1 |
| Randi, ML | 2 |
| Rossi, C | 1 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Bolinger, AM | 1 |
| Zangwill, AB | 1 |
| Glidden, D | 1 |
| DeSantes, K | 1 |
| Heyn, L | 1 |
| Risler, LJ | 1 |
| Bostrom, B | 1 |
| Cowan, MJ | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Poonkuzhali, B | 1 |
| Chandy, M | 1 |
| Srivastava, A | 1 |
| Dennison, D | 1 |
| Krishnamoorthy, R | 1 |
| Aker, M | 1 |
| Brautbar, C | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Gómez-Almaguer, D | 1 |
| Ruiz-Argüelles, A | 1 |
| González-Llano, O | 1 |
| Cantú, OG | 1 |
| Jaime-Pérez, JC | 1 |
| Hebart, H | 1 |
| Wuchter, P | 1 |
| Loeffler, J | 1 |
| Gscheidle, B | 1 |
| Hamprecht, K | 1 |
| Sinzger, C | 1 |
| Jahn, G | 1 |
| Dietz, K | 1 |
| Kanz, L | 1 |
| Einsele, H | 1 |
| Renner, UD | 1 |
| Kroschinsky, F | 1 |
| Johne, C | 1 |
| Jenke, A | 1 |
| Naumann, R | 1 |
| Bornhäuser, M | 1 |
| Dahllöf, G | 1 |
| Jönsson, A | 1 |
| Ulmner, M | 1 |
| Huggare, J | 1 |
| Mengarelli, A | 1 |
| Iori, A | 1 |
| Guglielmi, C | 1 |
| Romano, A | 1 |
| Cerretti, R | 1 |
| Torromeo, C | 1 |
| Micozzi, A | 1 |
| Fenu, S | 1 |
| Laurenti, L | 1 |
| Donato, V | 1 |
| De Felice, L | 1 |
| Holmström, G | 1 |
| Calissendorff, B | 1 |
| Ayas, M | 1 |
| Belgaumi, A | 1 |
| Al-Mahr, M | 1 |
| Al-Jefri, A | 1 |
| Solh, H | 1 |
| Leung, W | 1 |
| Kitajima, K | 1 |
| Raposa, T | 1 |
| Anger, G | 1 |
| Senf, L | 1 |
| Schmidt, U | 1 |
| Mattheus, A | 1 |
| MacDougall, BK | 1 |
| Weinerman, BH | 1 |
| Kemel, S | 1 |
| Stott, H | 1 |
| Fox, W | 1 |
| Girling, DJ | 1 |
| Stephens, RJ | 1 |
| Hamilton, PJ | 1 |
| Dawson, AA | 1 |
| MacEwen, EG | 1 |
| Drazner, FH | 1 |
| McClelland, AJ | 1 |
| Wilkins, RJ | 1 |
| Millar, BC | 1 |
| Bell, JB | 1 |
| Millar, JL | 1 |
| Montes, A | 1 |
| Joffe, JK | 1 |
| McElwain, TJ | 1 |
| Zambruno, G | 1 |
| Girolomoni, G | 1 |
| Manca, V | 1 |
| Andreani, M | 1 |
| Galimberti, M | 1 |
| Lucarelli, G | 1 |
| Giannetti, A | 1 |
| Yeager, AM | 3 |
| Graham, ML | 1 |
| Jones, RJ | 2 |
| Grochow, LB | 1 |
| Flowers, ME | 1 |
| Doney, KC | 2 |
| Storb, R | 4 |
| Sanders, JE | 4 |
| Sullivan, KM | 3 |
| Bryant, E | 1 |
| Witherspoon, RP | 2 |
| Myers, S | 1 |
| Devine, S | 1 |
| Larson, RA | 1 |
| Williams, SF | 1 |
| Park, CL | 1 |
| O'Toole, K | 1 |
| Chandler, C | 1 |
| Topper, RL | 1 |
| Essell, JH | 1 |
| Thompson, JM | 1 |
| Harman, GS | 1 |
| Halvorson, RD | 1 |
| Snyder, MJ | 1 |
| Johnson, RA | 1 |
| Rubinsak, JR | 1 |
| Grossi, A | 1 |
| Vannucchi, AM | 1 |
| Longo, G | 1 |
| Rafanelli, D | 1 |
| Rossi Ferrini, P | 1 |
| Vaughan, WP | 1 |
| Dennison, JD | 1 |
| Reed, EC | 1 |
| Klassen, L | 1 |
| McGuire, TR | 1 |
| Sanger, WG | 1 |
| Kumar, PP | 1 |
| Warkentin, PI | 1 |
| Gordon, BG | 1 |
| Bierman, PJ | 1 |
| Devergie, A | 1 |
| Esperou-Bourdeau, H | 1 |
| Ribaud, P | 1 |
| Traineau, R | 1 |
| Gluckman, E | 1 |
| Wiktor-Jedrzejczak, W | 1 |
| Szczylik, C | 1 |
| Matej, H | 1 |
| Pojda, Z | 1 |
| Ratajczak, MZ | 1 |
| Myc, A | 1 |
| Siekierzyński, M | 1 |
| Kansy, J | 1 |
| Kłos, M | 1 |
| Rybicki, Z | 1 |
| Emminger, W | 1 |
| Emminger-Schmidmeier, W | 1 |
| Phillips, GL | 1 |
| Shepherd, JD | 1 |
| Barnett, MJ | 1 |
| Lansdorp, PM | 1 |
| Klingemann, HG | 1 |
| Spinelli, JJ | 1 |
| Nevill, TJ | 1 |
| Chan, KW | 1 |
| Reece, DE | 1 |
| Van der Jagt, RH | 1 |
| Petersen, FB | 2 |
| Bigelow, CL | 1 |
| Fisher, LD | 1 |
| Schoch, GH | 1 |
| Klein, JP | 2 |
| Skolnick, A | 1 |
| Morgan, M | 1 |
| Dodds, A | 2 |
| Atkinson, K | 2 |
| Downs, K | 1 |
| Biggs, J | 2 |
| Cao, DC | 1 |
| Miclea, M | 1 |
| Tanzer, J | 1 |
| Lessard, M | 1 |
| Sigaux, F | 1 |
| Kaldor, JM | 1 |
| Day, NE | 1 |
| Pettersson, F | 1 |
| Clarke, EA | 1 |
| Pedersen, D | 1 |
| Mehnert, W | 1 |
| Bell, J | 1 |
| Høst, H | 1 |
| Prior, P | 1 |
| Karjalainen, S | 1 |
| Terenzi, A | 1 |
| Lubin, I | 1 |
| Lapidot, T | 1 |
| Salomon, O | 1 |
| Faktorowich, Y | 1 |
| Rabi, I | 1 |
| Martelli, MF | 1 |
| Reisner, Y | 1 |
| Rowley, SD | 1 |
| Cottler-Fox, M | 1 |
| Greenspan, A | 1 |
| Lynch, M | 1 |
| Sheridan, WP | 1 |
| Boyd, AW | 1 |
| Green, MD | 1 |
| Russell, DM | 1 |
| Thomas, RJ | 1 |
| McGrath, KM | 1 |
| Vaughan, SL | 1 |
| Scarlett, JD | 1 |
| Griffiths, JD | 1 |
| Brodie, GN | 1 |
| Clift, RA | 2 |
| Bearman, SI | 1 |
| Reynolds, M | 1 |
| McCann, SR | 1 |
| Kanfer, EJ | 1 |
| Fefer, A | 2 |
| Hill, RS | 1 |
| Amos, D | 1 |
| Shulman, HM | 1 |
| Noble, G | 1 |
| Ashby, M | 1 |
| Concannon, A | 1 |
| Burger, T | 1 |
| Schmelczer, M | 1 |
| Molnár, L | 1 |
| Pajor, L | 1 |
| Koszorús, S | 1 |
| Colvin, OM | 1 |
| Stuart, RK | 1 |
| Burke, PJ | 1 |
| Ambinder, RF | 1 |
| Virgolini, L | 1 |
| Hobbs, JR | 1 |
| Williamson, S | 1 |
| Chambers, JD | 1 |
| James, DC | 1 |
| Joshi, R | 1 |
| Shaw, P | 1 |
| Hugh-Jones, K | 1 |
| Ersbøll, J | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Schultz, H | 1 |
| Tsygankova, VA | 1 |
| Rudakov, IA | 1 |
| Möller, H | 1 |
| Waldenström, J | 1 |
| Goldman, JM | 1 |
| Baserga, A | 1 |
| Castoldi, GL | 1 |
| Sonnet, J | 1 |
| Michaux, JL | 1 |
| Hekster, C | 1 |
| Lemmel, EM | 1 |
| Motycka, K | 1 |
| Soucek, J | 1 |
| Nouza, K | 1 |
| Onicescu, D | 1 |
| Stoica, I | 1 |
| Tasca, L | 1 |
| Patakfalvi, A | 1 |
| Armstrong, JG | 1 |
| Bates, HA | 1 |
| Bankole, RO | 1 |
| Swaim, WR | 1 |
| Hörmann, W | 1 |
| Scheffel, G | 1 |
| Armbröster, E | 1 |
| Schwarz, MI | 1 |
| Whitcomb, ME | 1 |
| Goldman, AL | 1 |
| Fickers, M | 1 |
| Speck, B | 1 |
| Basu, B | 1 |
| Ray, B | 1 |
| Bhattacharya, DK | 1 |
| Chatterjee, GC | 1 |
| Schwartz, A | 1 |
| Stĕrba, J | 1 |
| Crowther, D | 1 |
| Prandota, J | 1 |
| Van Hove, WZ | 1 |
| Waldenström, JG | 1 |
| Visfeldt, J | 1 |
| Franzén, S | 1 |
| Nielsen, A | 1 |
| Tribukait, B | 1 |
| Gärtner, U | 1 |
| Schief, A | 1 |
| Rentsch, I | 1 |
| Nakao, K | 1 |
| Kinugasa, K | 1 |
| Fujioka, N | 1 |
| Sasa, S | 1 |
| Mizoguchi, H | 1 |
| Obrecht, P | 1 |
| Todo, A | 1 |
| Yoshida, Y | 1 |
| Sawada, H | 1 |
| Ward, HP | 1 |
| Block, MH | 1 |
| Wasserman, LR | 1 |
| Schmid, JR | 1 |
| Oechslin, RJ | 1 |
| Frick, PG | 1 |
| Silber, R | 1 |
| Unger, KW | 1 |
| Ellman, L | 1 |
| Marcolongo, R | 1 |
| Di Paolo, N | 1 |
| Bianco, G | 1 |
| Bravi, A | 1 |
| Hartwich, G | 1 |
| Butzler, W | 1 |
| Stecher, G | 1 |
| Reinhardt, G | 1 |
| Orzechowska, K | 1 |
| Kotlarek-Haus, S | 1 |
| von Sallmann, L | 1 |
| Grimes, P | 1 |
| Rohmann, I | 1 |
| Bartelheimer, H | 1 |
| Frenzel, H | 1 |
| Millard, RE | 1 |
| Lawler, SD | 1 |
| Kay, HE | 1 |
| Cameron, CB | 1 |
| Bishop, RC | 1 |
| Ward, HN | 1 |
| Konikov, N | 1 |
| Gruenwald, H | 1 |
| Kiossoglou, KA | 1 |
| Aleksandrov, VA | 1 |
| Staeuber, PG | 1 |
| Liss, E | 1 |
| Pease, GL | 1 |
| Zilocchi, C | 1 |
| Israëls, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation[NCT01257854] | 200 participants (Anticipated) | Observational | 2008-02-29 | Recruiting | |||
| A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells[NCT03538899] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2018-05-31 | Recruiting | ||
| NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430] | 30 participants (Anticipated) | Interventional | 2004-04-30 | Completed | |||
| HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY[NCT00732316] | Phase 2 | 54 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY[NCT01795378] | Phase 1/Phase 2 | 56 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen[NCT00556452] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome[NCT00774280] | Phase 3 | 130 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study[NCT01037764] | Phase 2 | 100 participants (Anticipated) | Interventional | 2010-01-31 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | ||
| [NCT00000603] | Phase 2 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069] | 876 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144] | Phase 2 | 50 participants | Interventional | 1999-10-31 | Completed | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of patients alive at 5 years (NCT00556452)
Timeframe: five years
| Intervention | Participants (Count of Participants) |
|---|---|
| Clo/BU4 | 6 |
Percent Overall Survival (OS) for at one year for subjects with Acute Myeloid Leukemia (AML). (NCT00556452)
Timeframe: 1 year
| Intervention | percent overall survival (Number) |
|---|---|
| Clo/BU4 | 48 |
Percent Overall Survival (OS) at two years for all patients. (NCT00556452)
Timeframe: 2 years
| Intervention | percent overall survival (Number) |
|---|---|
| Clo/BU4 | 28 |
The incidence of non-hematological toxicities (Common Terminology Criteria for Adverse Events (CTCAE) 3.0) from initiation of conditioning to Day + 30 or toxicities after day +30, possibly, probably or definitely related to conditioning for all patients treated with Clofarabine (independent of dose level). (NCT00556452)
Timeframe: two years
| Intervention | toxicities (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Liver | Gastrointestinal | Genito-Urinary | Cardiopulmonary | Neurologic | Skin | Other | |
| Clo/Bu4 | 56 | 70 | 4 | 10 | 8 | 11 | 3 |
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
34 reviews available for busulfan and Leucocythaemia
| Article | Year |
|---|---|
Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis.
Topics: Busulfan; Child; Cyclophosphamide; Humans; Leukemia; Transplantation Conditioning; Treatment Outcome | 2022 |
Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2010 |
Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; D | 2011 |
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoi | 2012 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA TO CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Cyclophosphamide; F | 1963 |
CYTOGENETIC STUDIES IN CHRONIC MYELOID LEUKEMIA.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Cytog | 1963 |
PORPHYRIA CUTANEA TARDA ASSOCIATED WITH CHRONIC GRANULOCYTIC LEUKEMIA TREATED WITH BUSULFAN (MYLERAN).
Topics: Busulfan; Feces; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Pigm | 1964 |
Bone marrow transplantation in acute nonlymphoblastic leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; C | 1984 |
The chronic leukemias.
Topics: Adult; Busulfan; Chromosomes, Human, 21-22 and Y; Chronic Disease; Humans; Leukemia; Leukemia, Hairy | 1980 |
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning].
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Arrhythmias, Cardiac; Bone Marrow Tran | 1995 |
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1993 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
[Total body irradiation in hematology: clinical indications and prospects].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
Tumor inductions by cytostatics in man.
Topics: 2-Naphthylamine; Alkylating Agents; Antineoplastic Agents; Busulfan; Carcinogens; Cocarcinogenesis; | 1975 |
Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Immunosuppression Therapy; | 1992 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; | 1992 |
[Essential thrombocythemia: conventional therapy].
Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo | 1991 |
Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosph | 1991 |
Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpl | 1990 |
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 1989 |
[Neutrophil leukemia. Review of the literature].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Busulfan; Fema | 1985 |
[Methods of studying blood thrombocytopoietic activity (literature review)].
Topics: Anemia; Animals; Blood Platelets; Blood Transfusion; Busulfan; Hemorrhage; Humans; Leukemia; Methods | 1972 |
Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review.
Topics: Animals; Antigens, Neoplasm; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1973 |
The spectrum of diffuse pulmonary infiltration in malignant disease.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Busulfan; Embolism, Fat; Hemorrhage; Hodgkin Disease; Humans; I | 1973 |
[Chemotherapy of chronic leukemias].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Chronic Disease; Cyclophosphamide; Humans; Hydroxyure | 1974 |
[Lactate dehydrogenase in human leukemia. A clinico-experimental study].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Bone Marrow; Bone Marrow Cells; Busulfan; Endotox | 1972 |
[Current status of prognosis and the factors affecting it in adult leukemia and malignant lymphoma].
Topics: Adolescent; Adult; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloi | 1967 |
[Therapy of chronic leukemia].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Female; Glucocorticoids; Humans; Leukemia; Leukemia, | 1968 |
[Biochemistry of antileukemic drugs].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Asparaginase; Busulfan; Chlorambu | 1970 |
[Nucleic acid metabolism of leukemia cell].
Topics: Busulfan; Cytarabine; Dexamethasone; DNA; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leuke | 1970 |
The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Androgens; Anemia; Animals; Blood Cell Count; Blood C | 1971 |
The management of polycythaemia vera.
Topics: Acute Disease; Alkylating Agents; Bloodletting; Bone Marrow Diseases; Busulfan; Humans; Leukemia; Ph | 1971 |
43 trials available for busulfan and Leucocythaemia
| Article | Year |
|---|---|
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospect | 2022 |
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Topics: Adolescent; Adult; Anemia, Aplastic; Busulfan; Cohort Studies; Cyclophosphamide; Follow-Up Studies; | 2009 |
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.
Topics: Adult; Busulfan; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic | 2011 |
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Busulfan; C | 2011 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteri | 2013 |
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etopo | 2002 |
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Cyclophosp | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompa | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplast | 2004 |
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Topics: Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Body Mas | 2006 |
Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; G | 2008 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combi | 2008 |
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta | 1995 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study.
Topics: Bone Marrow Transplantation; Busulfan; Costs and Cost Analysis; Double-Blind Method; Erythrocyte Tra | 1994 |
A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Immunosuppression Therapy; Leukemia | 1994 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1993 |
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Child, Preschool; C | 1994 |
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Mo | 1993 |
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.
Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Child; Chromatography, High Pressure | 1996 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi | 1996 |
Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Combine | 1996 |
Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Ch | 1996 |
High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosph | 1997 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta
Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Bronchiolitis Obliterans; Busulfan; Catara | 1999 |
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1999 |
Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up.
Topics: Aged; Aged, 80 and over; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survi | 1999 |
Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child; Combined Mod | 2000 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Enzyme | 2001 |
Treatment by radiophosphorus versus busulfan in polycythemia vera: a randomized trial (E.O.R.T.C.'s) "leukemias and hematosarcomas" group.
Topics: Busulfan; Clinical Trials as Topic; Female; Humans; Leukemia; Male; Middle Aged; Phosphorus Radioiso | 1977 |
Acute leukaemia after busulphan.
Topics: Acute Disease; Bronchial Neoplasms; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Hu | 1977 |
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1992 |
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U | 1992 |
Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1991 |
Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality | 1991 |
Leukemia following chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studie | 1990 |
Graft-versus-host disease: effects on long term disease free survival in marrow transplantation for haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1987 |
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, | 1986 |
360 other studies available for busulfan and Leucocythaemia
| Article | Year |
|---|---|
GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
Topics: Adolescent; Biomarkers, Tumor; Busulfan; Cell Line, Tumor; Cell Proliferation; Child; Child, Prescho | 2022 |
Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; M | 2022 |
Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospec
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2020 |
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies.
Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Pr | 2021 |
Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Drug Administratio | 2017 |
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematop | 2018 |
Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Female; Hematopoietic | 2019 |
A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan.
Topics: Adult; Aged; Busulfan; Chromatography, Liquid; Female; Hemoglobins; Humans; Leukemia; Lymphoma; Male | 2019 |
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Di | 2013 |
Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Antineoplastic Agents, | 2013 |
Intravenous versus oral busulfan-based conditioning for pediatric allogeneic hematopoietic cell transplantations: did the pendulum swing too far, too fast?
Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Myeloablative Ago | 2013 |
Ovarian function after allogeneic hematopoietic stem cell transplantation in childhood and adolescence.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Fert | 2014 |
Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Chimerism; Cyc | 2014 |
Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
Topics: Adolescent; Adult; Area Under Curve; Busulfan; Chromatography, High Pressure Liquid; Female; Half-Li | 2015 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem C | 2015 |
HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; G | 2015 |
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busul | 2016 |
Treatment of childhood leukemia with haploidentical hematopoietic stem cell transplantation using parent as donor: a single-center study of 111 case.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft | 2015 |
Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cytomega | 2015 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopo | 2016 |
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
Topics: Adenine Nucleotides; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Follow-Up Studies; Ha | 2017 |
Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation.
Topics: Adolescent; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bu | 2010 |
[A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cel | 2010 |
Leukemia with pigmentation.
Topics: Busulfan; Humans; Hyperpigmentation; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pig | 1965 |
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoi | 2012 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busul | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Body Composition; Body Mass Index; Busulfan; C | 2012 |
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; H | 2013 |
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hemato | 2002 |
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Topics: Adolescent; Adult; Autoantigens; Bilirubin; Biomarkers; Body Weight; Bone Marrow Transplantation; Bu | 2002 |
Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combine | 2002 |
[Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cel | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
[Myleran, a new cytostatic drug in leukemias].
Topics: Busulfan; Cytostatic Agents; Glycols; Leukemia; Leukemia, Myeloid | 1953 |
Myleran in chronic myeloid leukaemia; chemical constitution and biological action.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Le | 1953 |
Myleran in chronic myeloid leukaemia; results of treatment.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1953 |
[New therapy of leukoses; triethylene phosphoramide; G. T. 41 (myleran); 6-mercaptopurine; beta-mercaptoethylamine; massive doses of cortisone].
Topics: Busulfan; Cortisone; Cysteamine; Ethylamines; Leukemia; Mercaptopurine; Phosphoramides; Phosphorus; | 1953 |
The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or myleran) upon leukemia.
Topics: Busulfan; Leukemia | 1954 |
Myleran in chronic myeloid leukaemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1955 |
[The treatment of myelocytic leukemias with myleran and demecolcin].
Topics: Antineoplastic Agents; Busulfan; Colchicine; Glycols; Leukemia; Leukemia, Myeloid | 1955 |
[Temporary remission induced by 1,4-dimethylsulfonyloxybutane (myleran) in a case of myeloid leukemia in hemocytoblastic attack].
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myeloid; Leukocytes; Social Behavior | 1955 |
The use of myleran in the treatment of chronic myelocytic leukemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1955 |
[Trial chemotherapy of myeloid leukemia by three new substances: demecolcine, thiocolchicine, myleran].
Topics: Antineoplastic Agents; Busulfan; Colchicine; Demecolcine; Glycols; Leukemia; Leukemia, Myeloid | 1955 |
Treatment of chronic granulocytic leukemia with myleran.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
Myleran in treatment of chronic myeloid leukaemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
Myleran in the treatment of chronic granulocytic leukemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1956 |
[Effect of sulfabutin on leukocyte metabolism].
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myeloid; Leukocytes | 1955 |
Myleran therapy in malignant neoplastic disease; use of 1,4-dimethanesulfonyloxbutane with emphasis on chronic granulocytic leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms | 1956 |
Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (myleran).
Topics: Anemia; Anemia, Myelophthisic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1956 |
Chemotherapy of leukaemia. I. Myleran in the treatment of chronic myeloid leukaemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
Myleran in pregnancy; report of a case.
Topics: Busulfan; Leukemia; Leukemia, Myeloid; Pregnancy | 1956 |
The use of myleran and similar agents in chronic leukemias.
Topics: Busulfan; Humans; Leukemia | 1956 |
The use of myleran and similar agents in chronic leukemias.
Topics: Busulfan; Humans; Leukemia | 1956 |
The use of myleran and similar agents in chronic leukemias.
Topics: Busulfan; Humans; Leukemia | 1956 |
The use of myleran and similar agents in chronic leukemias.
Topics: Busulfan; Humans; Leukemia | 1956 |
Contribution to the study of the treatment of myeloid leukemia with misulban.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1956 |
Contribution to the study of the treatment of myeloid leukemia with misulban.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1956 |
Contribution to the study of the treatment of myeloid leukemia with misulban.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1956 |
Contribution to the study of the treatment of myeloid leukemia with misulban.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Myleran in chronic myelogenic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Treatment of chronic myeloid leukemia with 1, 4-butanediol dimethylsulfonyl ester (busulfan)].
Topics: Busulfan; Butylene Glycols; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1956 |
[Continuous therapy of chronic myeloid leukemia with myleran (sulfabutin)].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Speech | 1957 |
Myleran treatment in chronic granulocytic leukaemia.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1957 |
The treatment of chronic myeloid leukaemia with myleran.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
Case report chronic myelogenous leukemia; an eight year experience.
Topics: Blood Transfusion; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leu | 1957 |
[Myleran in chronic myeloid leukemia; importance of systematic maintenance therapy].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1956 |
[Colcemid and myleran in the treatment of chronic myelosis].
Topics: Busulfan; Colchicine; Demecolcine; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuke | 1957 |
[Cytostatic prolonged therapy in chronic leukemia].
Topics: Busulfan; Chronic Disease; Humans; Leukemia; Leukemia, Myeloid | 1957 |
Treatment of chronic granulocytic leukemia with myleran.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1957 |
[1-4-Dimethanesulfoxybutane therapy of chronic leukemic myeloses].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Treatment of chronic myelocytic leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
Myleran in chronic myelogenous living chemistry.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1957 |
Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.
Topics: Anemia; Anemia, Aplastic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1957 |
On the mechanism of action of myleran.
Topics: Busulfan; Leukemia; Leukemia, Myeloid; Uric Acid | 1957 |
[Early result of myleran therapy of chronic myeloid leukemias].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1957 |
[Myleran use in leukaemias].
Topics: Busulfan; Humans; Leukemia | 1957 |
[Complications during chemotherapy of chronic myeloleukemia].
Topics: Busulfan; Hematopoiesis; Humans; Leukemia; Leukemia, Myeloid | 1957 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1958 |
[Aplastic anemia following myleran treatment of chronic myeloid leukemia].
Topics: Anemia; Anemia, Aplastic; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1958 |
[Data on an unusual acute transformation in a case of chronic myeloid leukemia following dimethylsulfonoxy-butane therapy].
Topics: Blood; Busulfan; Butanes; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukem | 1958 |
Use of busulfan in myelogenous leukemia during pregnancy.
Topics: Busulfan; Female; Fetus; Humans; Leukemia; Leukemia, Myeloid; Pregnancy | 1958 |
[Myelosan (1,4-dimethanesulfoniloxybutane) and its significance in the therapy of chronic myeloleukosis].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid | 1958 |
[Treatment of chronic myeloleukosis with myelosan].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid | 1958 |
[Method of treatment of chronic myeloleukosis with myelosan].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid | 1958 |
[Prolonged remission in subacute myeloid leukemia achieved by consecutive administration of 6-mercaptopurine and myleran].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negativ | 1958 |
[Result of myleran therapy of leukemias in children].
Topics: Busulfan; Leukemia | 1958 |
[Myleran therapy of chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1958 |
[Treatment of chronic myeloid leukemia by means of a new chemical antiblastic agent, 1-4-dimethylsulfonoxy-butane].
Topics: Busulfan; Butanes; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Mye | 1958 |
[Effect of myleran on the number of neutrophils in healthy mice & in mice with leukemia & leukmoid reaction].
Topics: Animals; Busulfan; Leukemia; Leukemia, Experimental; Mice; Neutrophils | 1958 |
Busulfan (1, 4-dimethanesulfonyloxybutane, myleran); summary of clinical results.
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1958 |
Myleran and triethylene melamine in the treatment of chronic granulocytic leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Triethylene | 1958 |
Effect of my-leran and 6-mercaptopurine (6-MP) on the serum level of vitamin B12 in chronic myelocytic leukemia.
Topics: Busulfan; Hematinics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; | 1959 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. IV].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Uretha | 1959 |
[Bone marrow aplasia consecutive to myleran therapy of chronic myeloid leukemia].
Topics: Anemia, Aplastic; Bone Marrow; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1959 |
[Chronic myeloid leukosis treated with 1-4-dimethane sulfonyl oxybutane; secondary pancytopenia].
Topics: Anemia; Anemia, Aplastic; Busulfan; Humans; Leukemia; Leukemia, Myeloid; Pancytopenia; Tracheophyta | 1959 |
[Comparative evaluation of the effectiveness of certain therapeutic methods in chronic leukemias; roentgen rays, radioactive phosphorus, urethane, embichine, arsenic, myleran. V].
Topics: Arsenic; Busulfan; Chronic Disease; Leukemia; Phosphorus; Phosphorus, Dietary; Radioactivity; Uretha | 1959 |
[Immediate and remote results of treatment of patients with chronic myeloid leukosis with myelosan].
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1960 |
[Chemotherapy of leukemic myelosis with 1,4-dimethylsulfonoxybutane (myeleukon)].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1961 |
[Myleran therapy of leukemia complicating pregnancy].
Topics: Busulfan; Female; Leukemia; Pregnancy; Pregnancy Complications | 1960 |
[Total bone marrow aplasia caused by uncontrolled treatment with dimethanesulfonoxybutane in a case of chronic myelocytic leukemia].
Topics: Bone Marrow; Bone Marrow Diseases; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-A | 1960 |
[Experiences with sulfabutin in the therapy of chronic myelosis].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
[Clinico-laboratory data in myelosan therapy of patients with chronic myeloleukoses].
Topics: Busulfan; Leukemia; Leukemia, Myeloid | 1960 |
Leukocytic alkaline phosphatase in busulfan-induced remissions of chronic granulocytic leukemia.
Topics: Alkaline Phosphatase; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1961 |
[Chronic myeloid leukemia during pregnancy successfully treated with busulfan].
Topics: Busulfan; Female; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Pre | 1959 |
Transplacental transmission of busulfan (myleran) in a mother with leukemia. Production of fetal malformation and cytomegaly.
Topics: Busulfan; Congenital Abnormalities; Female; Leukemia; Mothers; Pregnancy; Pregnancy Complications | 1960 |
[Treatment of chronic myeloid leukemia with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1960 |
[Immediate results of treatment of chronic myelosis with myleran].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1959 |
Combined x-ray and myleran treatment of chronic myelosis.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; X-Rays | 1959 |
Myleran in the treatment of chronic myelogenous leukemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1959 |
[Bone marrow hematopoiesis in patients with chronic myelosis before and after treatment with myleran].
Topics: Bone Marrow; Busulfan; Hematopoiesis; Hematopoietic System; Leukemia; Leukemia, Myelogenous, Chronic | 1959 |
[Giant nuclei after myleran therapy and spleen irradiation in chronic myeloid leukemia].
Topics: Busulfan; Cell Nucleus; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1960 |
[Bone marrow aplasia in therapy of chronic myelosis with myleran].
Topics: Anemia, Aplastic; Bone Marrow; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1961 |
Busulphan in the treatment of chronic granulocytic leukaemia.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1961 |
[Effect of mannitolmyleran (1,6 dimethanesulfonoxy-D-mannitol) in chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mannitol | 1961 |
[Long-term chemotherapy of chronic myeloid leukemia with Myleran and C69].
Topics: Antineoplastic Agents; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemi | 1962 |
[Changes in antitoxic and prothrombin- and bilirubin-producing functions of the liver in patients with chronic myelosis treated with myelosan (Myleran)].
Topics: Bilirubin; Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; | 1962 |
[Treatment of chronic myeloid leukemia with Mannit-busulfan].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mannitol | 1961 |
[Treatment of chronic myelosis with Myleran (myeleukon) with special reference to alkaline leukocyte phosphatase activity].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukocytes; | 1961 |
Evaluation of the comparative effectiveness of Myleran and 6-MP in the management of patients with chronic myelocytic leukemia.
Topics: Busulfan; Disease Management; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, | 1962 |
[Treatment with myelosan of patients with chronic myeloid leukemia].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1962 |
Chronic myeloid leukaemia: cytogenetic studies before and after splenic irradiation.
Topics: Busulfan; Chromosomes; Cytogenetic Analysis; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-A | 1962 |
Leukemogenic effect of myleran on the mouse thymus.
Topics: Animals; Busulfan; Leukemia; Mice; Thymus Gland | 1961 |
[Cutaneous pigmentations during myeloid leukemia treated by Myleran].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Pigmentation Disorders; Skin Pigmentation | 1962 |
[Refractory myeloid leukemia].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Mercaptopurine; Prednisone | 1963 |
Chemotherapy of malignant disease. II. Diseases of lymphoid tissue and bone marrow.
Topics: Adrenal Cortex Hormones; Aged; Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Hodgkin Diseas | 1962 |
[Aplasia of the bone marrow in patients with chronic myelocytic leukemia treated with myelosan].
Topics: Anemia; Anemia, Aplastic; Bone Marrow; Busulfan; Humans; Leukemia; Leukemia, Myelogenous, Chronic, B | 1962 |
Cytologic dysplasia related to busulfan (Myleran) therapy. Report of a case.
Topics: Busulfan; Cervix Uteri; Female; Humans; Hyperplasia; Leukemia; Leukemia, Myeloid | 1963 |
Some immunologic aspects of the evolution and treatment of leukemia.
Topics: Animals; Biological Products; Busulfan; Humans; Leukemia; Mechlorethamine; Nitrogen Mustard Compound | 1962 |
[Forms of leukosis and their therapy].
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Busulfan; Colchicine; Folic Acid Antagonists; Go | 1963 |
Treatment of chronic leukaemia.
Topics: Busulfan; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid | 1962 |
Busulfan in pregnancy.
Topics: Busulfan; Female; Humans; Leukemia; Pregnancy; Pregnancy Complications | 1962 |
[Hazards of Myeleukon therapy].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid | 1961 |
Chronic granulocytic leukemia and cancer. Report of a case.
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Neoplasms; Rad | 1963 |
[CLASSIFICATION OF LEUKEMIA BY SENSITIVITY OF CELLS TO DRUGS].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antimetabolites; Antineoplastic Agents; Busulfan; Cl | 1963 |
DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY.
Topics: Busulfan; Diagnosis, Differential; Ergocalciferols; Humans; Leukemia; Leukemia, Myeloid; Neoplasms; | 1963 |
EXPERIMENTAL APPROACHES TO THE CHEMOTHERAPY OF LEUKAEMIA.
Topics: Busulfan; Chlorambucil; Leukemia; Leukemia, Experimental; Neoplasms; Rats; Research | 1963 |
[THERAPY OF HEMATODERMIAS].
Topics: Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Dermatology; Hydrocortisone; Leukemia; Lymphoma | 1963 |
[EXAMINATION OF THE STEROID METABOLISM IN HUMAN LEUKEMIA].
Topics: 17-Ketosteroids; Androgens; Busulfan; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Lymph | 1963 |
LEUKEMIA. AN ANALYSIS OF 209 CASES FROM THE ELLIS FISCHEL STATE CANCER HOSPITAL.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Cancer Care Facilit | 1963 |
THE MANAGEMENT OF LEUKAEMIA IN CHILDHOOD.
Topics: Busulfan; Child; Cyclophosphamide; Disease Management; Leukemia; Mercaptopurine; Methotrexate; Predn | 1963 |
DRUGS IN THE TREATMENT OF LEUKAEMIA.
Topics: Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; M | 1963 |
[CHRONIC MYELOID LEUKOSIS IN CHILDREN: 4 CASES].
Topics: Blood Platelet Disorders; Busulfan; Child; Humans; Leukemia; Leukemia, Myeloid; Leukocytosis; Lymph | 1963 |
[THE ROLE OF THE PLASMA FACTOR IN LEUKOCYTOPOIESIS].
Topics: Agranulocytosis; Busulfan; Hematopoiesis; Hypersplenism; Leukemia; Leukemia, Lymphoid; Leukemoid Rea | 1963 |
EFFECT OF DRUGS ON CELLS IN VITRO.
Topics: Animals; Busulfan; Glioma; In Vitro Techniques; Leukemia; Leukemia, Experimental; Leukemia, Myeloid; | 1963 |
THE LOCAL INFLAMMATORY RESPONSE IN PATIENTS WITH BLOOD DYSCRASIAS AS TESTED BY THE SKIN WINDOW TECHNIQUE.
Topics: Busulfan; Hodgkin Disease; Inflammation; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocyte | 1963 |
[THE USE OF DOPAN AND MYELOSAN IN THE TREATMENT OF PATIENTS WITH CHRONIC MYELOLEUKEMIA].
Topics: Busulfan; Leukemia; Leukemia, Myeloid; Nitrogen Mustard Compounds; Uracil Mustard | 1963 |
EFFECT OF ADMINISTRATION OF ALKYLATING AGENTS OR 6-MERCAPTOPURINE ON SERUM LEVEL OF DEOXYRIBONUCLEASE I IN LEUKEMIA PATIENTS.
Topics: Alkylating Agents; Blood Chemical Analysis; Busulfan; Deoxyribonuclease I; DNA; Humans; Leukemia; Le | 1963 |
EOSINOPHILIC LEUKEMIA PRESENTING WITH ERYTHROCYTOSIS.
Topics: Black People; Bone Marrow Diseases; Busulfan; Eosinophilia; Erythrocytes; Humans; Hypereosinophilic | 1963 |
[ULTRASTRUCTURAL MODIFICATIONS OF LEUKEMIC CELLS IN THE COURSE OF TREATMENT WITH ANTIPROLIFERATIVE DRUGS].
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Blood Cells; Busulfan; Electrons; Geriatrics; Le | 1963 |
THE TREATMENT OF LEUKEMIA.
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Leukemia; Mercaptopurine; Methotrex | 1964 |
[REMOTE RESULTS OF MYELOSAN THERAPY OF CHRONIC MYELOID LEUKEMIA].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Neoplasms | 1963 |
[CHRONIC LEUKEMIA. RECENT DATA ON ITS DIAGNOSIS AND TREATMENT].
Topics: Busulfan; Child; Chronic Disease; Leukemia; Leukemia, Myeloid; Neoplasms | 1963 |
[IMPROVEMENT AND EXACERBATION IN LEUKEMIA].
Topics: Aminocaproates; Aminocaproic Acid; Anemia; Antineoplastic Agents; Blood Transfusion; Busulfan; Centr | 1963 |
[PRESENT STATUS OF LEUKEMIA CHEMOTHERAPY].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Busulfan; Folic Acid Antagonists; Humans; Leukemia; | 1963 |
[HOW TO TREAT LEUKEMIA IN 1963].
Topics: Busulfan; Child; Chlorambucil; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopuri | 1963 |
MULTIVARIATE COMPARISON OF RESULTS OF TREATMENT IN CHRONIC LYMPHOCYTIC AND CHRONIC GRANULOCYTIC LEUKEMIA.
Topics: Antineoplastic Agents; Blood Platelets; Busulfan; Chlorambucil; Factor Analysis, Statistical; Hemogl | 1964 |
CHRONIC MYELOID LEUKEMIA WITH PRIAPISM IN EIGHT-YEAR-OLD CHILD.
Topics: Blood Chemical Analysis; Blood Platelets; Busulfan; Child; Chromosome Aberrations; Erythrocyte Count | 1964 |
[OBSERVATIONS ON A CASE OF CHRONIC MYELOID LEUKOSIS MASKED BY TREATMENT WITH 1-4-DIMETHANESULFONOXYBUTANE].
Topics: Anemia; Anemia, Aplastic; Busulfan; Gastrointestinal Hemorrhage; Leukemia; Leukemia, Myeloid; Toxico | 1963 |
CHROMOSOME ABNORMALITY WITH LYMPHOID LEUKAEMIA.
Topics: Abnormalities, Drug-Induced; Busulfan; Child; Chromosome Aberrations; Chromosome Disorders; Humans; | 1964 |
COMPARISON OF CYCLOPHOSPHAMIDE (CYTOXAN AND URACIL MUSTARD (U-8344) IN CHRONIC GRANULOCYTIC LEUKEMIA.
Topics: Adolescent; Busulfan; Cyclophosphamide; Geriatrics; Leukemia; Leukemia, Lymphoid; Leukemia, Myelogen | 1964 |
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II].
Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X- | 1964 |
IN-VITRO SENSITIVITY TESTS OF LEUKAEMIC CELLS TO CHEMOTHERAPEUTIC AGENTS.
Topics: Aminopterin; Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Geriatrics; H | 1964 |
[CYTOSTATIC THERAPY].
Topics: Antineoplastic Agents; Breast Neoplasms; Busulfan; Chlorambucil; Colchicine; Cyclophosphamide; Femal | 1964 |
DIABETES INSIPIDUS SECONDARY TO ACUTE LEUKEMIA. A CASE REPORT.
Topics: Autopsy; Bone Marrow Examination; Busulfan; Diabetes Insipidus; Diabetes Insipidus, Neurogenic; Huma | 1964 |
[APROPOS OF 2 CASES OF CUTANEOUS PIGMENTATION DURING MYELOID LEUKEMIA TREATED BY MYLERAN].
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Pigmentation Disorders; Skin Pigmentation; Toxicology | 1964 |
THE GRANULOCYTE RESPONSE TO ENDOTOXIN IN PATIENTS WITH HEMATOLOGIC DISORDERS.
Topics: Bone Marrow; Busulfan; Endotoxins; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Mye | 1964 |
DEFICIENCY OF THE HYDRAZINE SENSITIVE COMPONENT OF COMPLEMENT IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA.
Topics: Animals; Blood Protein Electrophoresis; Busulfan; Complement System Proteins; Erythrocytes; Guinea P | 1963 |
[MYELOBLASTIC ATTACKS IN CHRONIC MYELOLEUKOSIS AND THEIR TREATMENT].
Topics: Busulfan; Leukemia; Leukemia, Myeloid; Neoplasms; Toxicology | 1963 |
[COMBINED TREATMENT OF CHRONIC MYELOCYTIC LEUKEMIA].
Topics: Blood Transfusion; Busulfan; Cortisone; Erythrocyte Count; Hemoglobinometry; Humans; Leukemia; Leuke | 1963 |
THE CYTOSTATIC ACTION OF VINCALEUKOBLASTINE.
Topics: Aziridines; Blood Platelets; Bone Marrow; Busulfan; Cell Division; Colchicine; Erythropoiesis; Hemat | 1964 |
EXPERIMENTAL STUDY OF OLIVOMYCIN, AN ANTITUMOUR ANTIBIOTIC.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Carcin | 1964 |
EFFECT OF ANTI-LEUKAEMIC AGENTS ON CERTAIN PARASITIC INFESTATIONS IN MAN.
Topics: Busulfan; Drug Therapy; Helminthiasis; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopuri | 1964 |
HYPERPIGMENTATION OF THE SKIN IN PATIENTS WITH BUSULFAN (MYLERAN) THERAPY.
Topics: Busulfan; Hyperpigmentation; Leukemia; Leukemia, Myeloid; Melanosis; Toxicology | 1963 |
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi | 1964 |
CHRONIC LEUKEMIA.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Alkylating Agents; Anemia; Anemia, Hemolytic, | 1964 |
PRESENT STATUS OF LEUKEMIA IN JAPAN WITH SPECIAL REFERENCE TO EPIDEMIOLOGY AND STUDIES ON THE EFFECT OF CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Asian People; Busulfan; DNA; DNA, Neoplasm; Epidemio | 1964 |
SKIN LESIONS IN CHRONIC MYELOID LEUKAEMIA.
Topics: Blood Transfusion; Busulfan; Dermatology; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL | 1964 |
SUBMETACENTRIC CHROMOSOME IN CHRONIC MYELOCYTIC LEUKEMIA.
Topics: Busulfan; Chromosomes; Drug Therapy; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leu | 1964 |
PLASMA FACTORS IN LEUKAEMIA. IMMUNOLOGICAL AND "IN VITRO" CULTURAL STUDIES.
Topics: Blood Group Antigens; Busulfan; Chlorambucil; Complement Fixation Tests; Coombs Test; Humans; In Vit | 1964 |
THE MANAGEMENT OF LEUKEMIA AND LYMPHOMA.
Topics: Adrenal Cortex Hormones; Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Hodgkin Disease; Human | 1964 |
A CYTOGENETIC STUDY ON THE THERAPEUTIC EFFECT OF MYLERAN IN A CASE OF CHRONIC MYELOID LEUKAEMIA.
Topics: Busulfan; Chromosomes; Cytogenetic Analysis; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, | 1963 |
[STUDY OF THE CHROMOSOMES IN CHRONIC GRANULOCYTIC LEUKEMIA].
Topics: Busulfan; Chromosomes; Genetics, Medical; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1964 |
SEVERAL CELL-LINES WITH ABNORMAL KARYOTYPES IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKAEMIA.
Topics: Abnormal Karyotype; Blood Cell Count; Bone Marrow Examination; Busulfan; Chromosome Aberrations; Chr | 1964 |
LEUKEMIC MILIARY NODULES IN THE RETINA.
Topics: Busulfan; Eye Manifestations; Eye Neoplasms; Humans; Leukemia; Leukemia, Myeloid; Pathology; Retina; | 1964 |
BREAST CANCER AND CYTOLOGIC DYSPLASIA IN MANY ORGANS AFTER BUSULFAN (MYLERAN).
Topics: Breast Neoplasms; Busulfan; Drug Therapy; Humans; Hyperplasia; Leukemia; Leukemia, Myeloid; Neoplasm | 1964 |
ANTI-LEUKAEMIC DRUGS.
Topics: Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; M | 1964 |
A CLINICAL STUDY OF TWENTY CASES OF ERYTHROLEUKEMIA (DI GUGLIELMO'S SYNDROME).
Topics: Adrenal Cortex Hormones; Azaserine; Busulfan; Diagnosis, Differential; Drug Therapy; Humans; Leukemi | 1964 |
DIAGNOSTIC VALUE OF ALKALINE PHOSPHATASE IN LEUKOCYTES.
Topics: Alkaline Phosphatase; Busulfan; Celiac Disease; Diagnosis, Differential; Drug Therapy; Gout; Heart D | 1964 |
HAEMOPERICARDIUM IN CHRONIC MYELOID LEUKAEMIA.
Topics: Adolescent; Busulfan; Drug Therapy; Electrocardiography; Hemorrhage; Humans; India; Joint Diseases; | 1964 |
[HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
Topics: Anemia; Anemia, Hypochromic; Blood Platelets; Busulfan; Gastrointestinal Hemorrhage; Hemorrhage; Hem | 1964 |
GRANULOCYTIC LEUKAEMIA IN CHILDHOOD.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Blood Cell Count; Bone Marrow Examination; Busulfan; | 1964 |
EOSINOPHILIC LEUKAEMIA WITH PH1-POSITIVE CELLS.
Topics: Busulfan; Chromosome Aberrations; Chromosome Disorders; Eosinophilia; Humans; Hypereosinophilic Synd | 1964 |
DIHYDROXYBUSULFAN (NSC-39069) IN CHRONIC MYELOCYTIC LEUKEMIA AND MISCELLANEOUS MALIGNANT NEOPLASMS.
Topics: Busulfan; Drug Therapy; Geriatrics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk | 1964 |
[DIPLO-PH 1-CHROMOSOME IN MYELOID LEUKEMIA].
Topics: Busulfan; Chromosomes; Drug Therapy; Humans; Leukemia; Leukemia, Myeloid; Osteochondritis; Philadelp | 1964 |
PRESENCE OF TWO PH-1 CHROMOSOMES IN CELLS FROM A PATIENT WITH CHRONIC GRANULOCYTIC LEUKAEMIA.
Topics: Bone Marrow Examination; Busulfan; Chromosome Aberrations; Drug Therapy; Humans; Leukemia; Leukemia, | 1965 |
[ON THROMBOCYTOSIS IN CHILDREN].
Topics: Blood Platelets; Busulfan; Child; Drug Therapy; Leukemia; Leukemia, Myeloid; Thrombocytosis; Toxicol | 1964 |
FURTHER OBSERVATIONS ON LATE SOMATIC EFFECTS OF RADIOMIMETIC CHEMICALS AND X-RAYS IN MICE.
Topics: Aging; Busulfan; Cataract; Female; Humans; Leukemia; Leukemia, Myeloid; Longevity; Lung Neoplasms; L | 1965 |
CHRONIC MYELOID LEUKAEMIA IN CHILDREN.
Topics: Adolescent; Busulfan; Child; Humans; India; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 1965 |
[A CASE OF LEUKEMIA IN A LACTATING FEMALE: EFFECT OF TREATMENT WITH BUSULFAN ON THE INFANT].
Topics: Breast Feeding; Busulfan; Drug Therapy; Female; Humans; Infant; Infant, Newborn; Lactation; Leukemia | 1964 |
[MODERN TREATMENT OF LEUKEMIA].
Topics: Agranulocytosis; Busulfan; Chlorambucil; Cyclophosphamide; Drug Therapy; Genetic Diseases, X-Linked; | 1965 |
SOME BIOCHEMICAL ASPECTS OF LEUKAEMIAS: THE APPEARANCE OF A SOLUBLE DISULPHIDE IN THE BLOOD IN CHRONIC GRANULOCYTIC LEUKAEMIA.
Topics: Biochemical Phenomena; Biochemistry; Blood Chemical Analysis; Busulfan; Disulfides; Erythrocytes; Gl | 1964 |
BUSULFAN IN PREGNANCY: REPORT OF A CASE.
Topics: Busulfan; Drug Therapy; Female; Fetus; Humans; Leukemia; Leukemia, Myeloid; Pharmacology; Pregnancy; | 1965 |
STEROID HORMONE METABOLISM IN CHRONIC MYELOGENOUS LEUKEMIA.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Androgens; Androsterone; Busulfan; Cyclophosphamide; Dehyd | 1965 |
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS.
Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1965 |
GASTRIC PLASMACYTOMA (OR LYMPHOMA) FOLLOWED BY CHRONIC MYELOID LEUKAEMIA: A RARE LYMPHO-MYELO-PROLIFERATIVE DISORDER.
Topics: Anemia; Anemia, Macrocytic; Blood Cell Count; Busulfan; Drug Therapy; Gastrectomy; Humans; Leukemia; | 1965 |
BUSULFAN THERAPY OF MYELOCYTIC LEUKEMIA DURING PREGNANCY.
Topics: Busulfan; Drug Therapy; Female; Humans; Leukemia; Leukemia, Myeloid; Pregnancy; Pregnancy Complicati | 1965 |
[BIOPTIC STUDIES ON THE PROBLEM OF THERAPY-INDUCED BONE MARROW FIBROSES IN CHRONIC MYELOID LEUKEMIA].
Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1965 |
[SUPPORTIVE THERAPY IN CHRONIC MYELOCYTIC LEUKEMIA].
Topics: Busulfan; Drug Therapy; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloi | 1964 |
[MELANODERMA IN THE COURSE OF TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH MYLERAN].
Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia | 1965 |
LEUKAEMIA IN CHILDREN.
Topics: Adolescent; Black People; Bone Marrow Examination; Busulfan; Child; Chromosome Aberrations; Cyclopho | 1965 |
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Drug Therapy; Humans; Infant; | 1965 |
[Myleran in the treatment of chronic myelocytic leukemia].
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1954 |
[Progress in chemotherapy of myeloid leukemia: 1,4-butanediol dimethylsulfonyl ester (myleran, G.T. 41)].
Topics: Busulfan; Butylene Glycols; Glycols; Humans; Leukemia; Leukemia, Myeloid | 1955 |
Myleran (GT 41) in the treatment of leukaemia.
Topics: Busulfan; Glycols; Leukemia | 1955 |
Clinical experience with myleran in the treatment of leukemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myeloid | 1955 |
Myleran: a review of its action and a report on its use in chronic myeloid leuchaemia.
Topics: Busulfan; Glycols; Leukemia; Leukemia, Myeloid | 1955 |
[Chemotherapy of myeloid leukemia; 1,4-butanediol dimethylsulfonyl ester (Myleran G. T. 41)].
Topics: Busulfan; Butylene Glycols; Esters; Glycols; Leukemia; Leukemia, Myeloid | 1955 |
[The treatment of patients with chronic myeloid leukemia with myleran in polyclinical conditions].
Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 1960 |
[Pregnancy in a woman with chronic myelocytic leukemia treated with myleran].
Topics: Busulfan; Female; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Pre | 1960 |
Acute myeloblastic transformation after busulfan treatment of chronic myelocytic leukemia.
Topics: Busulfan; Granulocyte Precursor Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Pos | 1959 |
[On cytopenia in a female patient with chronic myeloid leukemia following myelosan therapy].
Topics: Anemia; Anemia, Aplastic; Busulfan; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-AB | 1962 |
Leukemia and pregnancy: observation of a case treated with busulfan (myleran).
Topics: Busulfan; Leukemia; Pregnancy | 1961 |
The role of Myleran in acute myelocytic leukemia.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1961 |
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.
Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antig | 2003 |
Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen.
Topics: Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Graft vs Hos | 2004 |
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Cyclophosphamide; Half-Life; Hematopo | 2004 |
Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
Topics: Administration, Oral; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Humans | 2005 |
Extracorporeal photo-chemotherapy for graft-versus-host disease.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pho | 2005 |
Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematologic | 2005 |
Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 2005 |
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Survival; Humans; Leukemia; Neurob | 2006 |
Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell C | 2006 |
[Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
Topics: Adult; Busulfan; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Heparin; | 2007 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antig | 2007 |
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Dis | 2007 |
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infectio | 2007 |
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs | 2007 |
[Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hum | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C | 2007 |
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, | 2008 |
Busulfan treatment of leukemia during pregnancy. Case report and review of the literature.
Topics: Adult; Busulfan; Female; Fetus; Humans; Infant, Newborn; Leukemia; Pregnancy; Pregnancy Complication | 1967 |
The effect of mannitol-myleran and two new dibromo-hexitols on the metabolic activities of nucleic acids and proteins. I.
Topics: Alkanes; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bromine; Busulfan; Carbohyd | 1967 |
Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Carmustine; Cytomegalovirus Infections; Gra | 1980 |
Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Combine | 1983 |
Sowing hematopoietic seeds.
Topics: Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Humans; Leukemia | 1983 |
Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1984 |
Serial in vitro bone marrow fibroblast culture in human leukemia.
Topics: Acute Disease; Adult; Aged; Bone Marrow Cells; Busulfan; Colony-Forming Units Assay; Culture Techniq | 1983 |
Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation.
Topics: Analysis of Variance; Bone Marrow Transplantation; Busulfan; Graft vs Host Reaction; Humans; Leukemi | 1982 |
Allogeneic bone marrow transplantation for blood cell disorders.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Animals; Bone Marrow Transplantation; Busulfan; | 1982 |
Treosulphan.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Busulfan; Carcinogens; Chemical Phenomena; Chemis | 1981 |
Marrow transplantation in acute leukemia following busulfan and cyclophosphamide.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; | 1980 |
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).
Topics: Adult; Aged; Busulfan; Chromosome Aberrations; Female; Humans; Leukemia; Middle Aged; Neoplasms, Mul | 1980 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantati | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycl | 1995 |
Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation?
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Humans; Leukem | 1995 |
Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1994 |
Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclop | 1994 |
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1994 |
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Diazepam; Drug Interactions | 1993 |
Factors affecting hair regrowth after bone marrow transplantation.
Topics: Adolescent; Adult; Age Factors; Alopecia; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan | 1993 |
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1993 |
The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; B-Lymphocytes; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cell Survival; | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood a
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantati | 1996 |
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience.
Topics: Adolescent; Adult; Blood Donors; Busulfan; Child; Child, Preschool; Cyclosporine; Erythropoietin; Fe | 1996 |
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
Topics: Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinophilia; Graft vs Hos | 1996 |
[Radioactive phosphorus (32P); an old but not bad treatment for polycythemia vera].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Leukemi | 1996 |
Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Topics: Administration, Oral; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Co | 1996 |
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1996 |
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Dise | 1997 |
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; | 1997 |
Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Busulfan; Dimethyl Sulfoxide; Dogs; H | 1998 |
Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children.
Topics: Adolescent; Age Factors; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclosporine; Cyst | 1998 |
Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Surv | 1999 |
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Body Height; Bone Marrow Transplantation; Busulfan | 1999 |
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Combined Mo | 1999 |
[Analysis of pulmonary function in leukemia patients after bone marrow transplantation: effects of prior chemotherapy].
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Female; Humans; Immunosuppr | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Genetic Diseases | 2000 |
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; C | 2001 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow- | 2001 |
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cells, Cultured; Cytomegalovirus; Cytomega | 2001 |
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; | 2001 |
Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Craniomandibular Disorders; Cyclophosphami | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; | 2002 |
Cataract in children after bone marrow transplantation: relation to conditioning regimen.
Topics: Bone Marrow Transplantation; Busulfan; Cataract; Cataract Extraction; Child; Child, Preschool; Femal | 2002 |
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etopo | 2002 |
[Leukemia planning of chemotherapy].
Topics: Aged; Busulfan; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia; Leukemia, | 1975 |
Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatics in vitro and in lymphocytes of leukaemic patients under cytostatic therapy.
Topics: Antineoplastic Agents; Busulfan; Cells, Cultured; Chlorambucil; Chromatids; Crossing Over, Genetic; | 1978 |
[Determination of serum vitamin B12 in hematologic diseases].
Topics: Acute Disease; Anemia, Pernicious; Busulfan; Hematologic Diseases; Humans; Leukemia; Leukemia, Myelo | 1979 |
Treatment of polycythemia vera.
Topics: Acute Disease; Adult; Aged; Bloodletting; Busulfan; Evaluation Studies as Topic; Female; Humans; Leu | 1979 |
Successful treatment of apparent eosinophilic leukaemia.
Topics: Busulfan; Eosinophils; Humans; Leukemia; Male; Middle Aged; Prednisolone | 1977 |
Diagnostic and therapeutic approach to chronic leukaemia.
Topics: Busulfan; Chlorambucil; Chronic Disease; Diagnosis, Differential; Glucocorticoids; Leukemia; Leukemi | 1975 |
Treatment of basophilic leukemia in a dog.
Topics: Animals; Basophils; Bone Marrow; Bone Marrow Cells; Busulfan; Dog Diseases; Dogs; Erythrocyte Count; | 1975 |
Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro.
Topics: Bone Marrow Cells; Busulfan; Cells, Cultured; Colony-Stimulating Factors; Combined Modality Therapy; | 1992 |
Epidermal Langerhans cells after allogeneic bone marrow transplantation: depletion by chemotherapy conditioning regimen alone.
Topics: Adolescent; Adult; Antigens, CD; Antigens, CD1; beta-Thalassemia; Bone Marrow Transplantation; Busul | 1992 |
Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Dose-Response Relationship, Drug; Female; H | 1992 |
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1992 |
Endocrine problems in children after bone marrow transplant for hematologic malignancies. The Long-term Follow-up Team.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Endocr | 1991 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclopho | 1991 |
Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Gr | 1991 |
Allogeneic bone marrow transplantation for leukemia using chemotherapy as conditioning: 6-year results of a single institution trial.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Leukemia; Survival Analysis | 1991 |
Making bone marrow transplants more safe.
Topics: Bone Marrow Transplantation; Busulfan; Clinical Protocols; Cyclophosphamide; Humans; Leukemia; Whole | 1991 |
The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cystitis; Drug Therapy, | 1991 |
Bone marrow transplantation for leukemia after conditioning with busulfan and cyclophosphamide. Bone marrow morphology in the early recovery phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1991 |
Chronic myelocytic leukaemia with unusual (27 years) complete remission terminating in acute undifferentiated leukaemia: a clinical and karyotypic study.
Topics: Busulfan; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; T | 1991 |
Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Chimera; Cyclophosphamide; Female; Leukemia; Lymphoc | 1990 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Graft vs Host D | 1989 |
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1989 |
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Dr | 1989 |
A comparison between regimens containing chemotherapy alone (busulfan and cyclophosphamide) and chemotherapy (V. RAPID) plus total body irradiation on marrow engraftment following allogeneic bone marrow transplantation.
Topics: Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Survival; Colony-Forming | 1989 |
Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; | 1987 |
Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cystitis; Hemorrhage; Hepatic Veno-Occlusiv | 1987 |
[Clinical course and transformation of polycythemia vera and its relation to applied therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chlorambucil; Combined Modali | 1987 |
Use of donors sharing one genetic haplotype for bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporins; Dose-Response Relationship, I | 1985 |
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot | 1985 |
Letter: Bone marrow damage during treatment of psoriasis with busulphan.
Topics: Acute Disease; Aged; Autopsy; Blood Platelet Disorders; Bone Marrow Diseases; Busulfan; Hematoma; Hu | 1973 |
Leucocyte separation and transfusion.
Topics: ABO Blood-Group System; Blood Group Incompatibility; Blood Transfusion; Busulfan; Cell Separation; C | 1974 |
Sex chromatin after cytostatic drugs.
Topics: Busulfan; Cell Nucleus; Humans; Leukemia; Leukocytes; Mercaptopurine; Mouth Mucosa; Sex Chromatin | 1966 |
Incidence and forms of leukaemia among the Congolese Bantus.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Blood Protein Electrophoresis; Blood Sedimen | 1966 |
[The influence of age and experimentally-induced disease on the tolerance of cytostatically-active materials in mice].
Topics: Age Factors; Aminopterin; Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; | 1967 |
A histochemical study on the dihydrofolate reductase activity in leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Histocytochemistry; Humans; Leukemia; Leukemia, Myeloid; Leukemia | 1973 |
Secondary antibody deficiency syndrome in haemoblastosis.
Topics: Agammaglobulinemia; Antibodies; Antigens, Bacterial; Blood Protein Disorders; Blood Proteins; Busulf | 1972 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Immunofluorescence studies in human leukemia.
Topics: Absorption; Antibodies, Anti-Idiotypic; Busulfan; Fluorescent Antibody Technique; Hodgkin Disease; H | 1969 |
[Studies of leukocyte metabolism. V. NAD and ATP in isolated leukocytes and erythrocytes in human leukemias under the effect of cytostatic compounds C73, busulfan and cyclophosphamide].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Busulfan; Cyclophosphamide; Depression, Chemical; Ery | 1970 |
Thrombocythaemia. Familial occurrence and transition into blastic crisis.
Topics: Alkaline Phosphatase; Anemia, Aplastic; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; | 1974 |
Studies on several enzymes of uronic acid pathway in human leucocytes under normal and leukemic conditions.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Ascorbic Acid; Busulfan; Carboxy-Lyases; Child, Preschoo | 1973 |
[Busulfan lung. Lung lesions due to cytostatics (author's transl)].
Topics: Antineoplastic Agents; Autopsy; Busulfan; Child; Female; Humans; Leukemia; Male; Mercaptopurine; Met | 1973 |
Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II.
Topics: Antineoplastic Agents; Brain Neoplasms; Busulfan; Cell Count; Cell Division; Cytarabine; Diffusion; | 1974 |
From bad to worse? Treatment and leukemogenesis.
Topics: Antibiotics, Antineoplastic; Busulfan; Chlorambucil; Chromosome Aberrations; Chromosome Disorders; H | 1973 |
Primary polycythaemia. 3. Studies on the significance of the history of the disease and of the treatment for the development of clones in bone marrow cells.
Topics: Adult; Aged; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Transformation, Neoplastic; Clone Cells; | 1973 |
[Myelofibrosis and leukemia (author's transl)].
Topics: Adolescent; Adult; Alkaline Phosphatase; Busulfan; Female; Glucosephosphate Dehydrogenase; Humans; L | 1973 |
Cell proliferation in leukemia during relapse and remission. 2. DNA synthesis of leukemic cells in the peripheral blood in vitro.
Topics: Adult; Aged; Blood Circulation; Busulfan; DNA; Female; Humans; In Vitro Techniques; Leukemia; Leukem | 1967 |
RNA metabolism in normal and leukaemic leucocytes: further studies on RNA synthesis.
Topics: Antimetabolites; Busulfan; Carbon Isotopes; Chromatography; Humans; Leukemia; Leukemia, Lymphoid; Le | 1968 |
[Clinical usefulness of eticholanolone in the evaluation of bone marrow reserves in patients treated with myelosuppressive drugs and with radiotherapy].
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Diseases; Bone Marrow Examination | 1969 |
[Secondary tumors in hemoblastoses during cytostatic treatment].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Bronchial Neoplasms; Busulfan; Carcinoma; Chlo | 1971 |
Some problems in the management of leukaemia and lymphoma.
Topics: Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1966 |
Chemotherapy in polycythemia vera.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid; Phosphorus Isotopes; Polycythemia Vera; Primary Myelo | 1968 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta | 1970 |
Pipobroman (Vercyte) - a new antineoplastic drug.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Bone Marrow; Busulfan; Chlorambucil; Gastrointestinal Hemo | 1967 |
[Coexistence of eosinophilic leukemia and prostatic carcinoma].
Topics: Busulfan; Eosinophils; Humans; Leukemia; Male; Middle Aged; Prostatic Neoplasms | 1969 |
The cataractogenic effect of dibromomannitol in rats.
Topics: Animals; Bromides; Busulfan; Cataract; DNA; Lens, Crystalline; Leukemia; Mannitol; Mitosis; Rats | 1970 |
[Do cytostatics change the histopathology of leukemias?].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Busulfan; Child; Cyclophosphamide; Fema | 1971 |
[Desired and undesirable effects of cytostatic therapy].
Topics: Androgens; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; E | 1967 |
Further observations on patients with a chromosomal abnormality associated with polycythaemia vera.
Topics: Adult; Autoradiography; Blood Cell Count; Blood Group Antigens; Blood Platelets; Bone Marrow; Bone M | 1968 |
Chemotherapy of Hodgkin's disease, lymphoma, and leukemia.
Topics: Adult; Antineoplastic Agents; Busulfan; Chlorambucil; Hodgkin Disease; Humans; Leukemia; Lymphoma; M | 1968 |
Cytologic dysplasia occurring after busulfan (Myleran) therapy. A syndrome resembling adrenocortical insufficiency and atrophic bronchitis.
Topics: Adrenal Insufficiency; Bone Marrow Examination; Bronchitis; Busulfan; Cell Nucleus; Cough; Cytodiagn | 1965 |
Philadelphia chromosome in eosinophilic leukemia.
Topics: Alkaline Phosphatase; Blood Transfusion; Bone Marrow Examination; Busulfan; Chromosome Aberrations; | 1965 |
[Teratogenic effect of the antileukemic drug--myelosan (myleron) on the rat embryo].
Topics: Abnormalities, Drug-Induced; Animals; Busulfan; Leukemia; Rats | 1965 |
[Chemotherapy of leukemia patients with Myelobromol].
Topics: Alkylating Agents; Animals; Blood Cell Count; Bromides; Busulfan; Humans; Injections, Intraperitonea | 1965 |
Basophilic leukemia.
Topics: Alkaline Phosphatase; Bone Marrow; Busulfan; Female; Humans; Leukemia; Male; Mast Cells; Middle Aged | 1966 |
[Considerations on therapy of 56 cases of leukemia in childhood].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Blood Transfusion; Busulfan; | 1966 |
Treatment and prognosis of polycythaemia managed by non-radioactive methods.
Topics: Blood Platelets; Busulfan; Humans; Leukemia; Phosphorus Isotopes; Polycythemia Vera; Pyrimethamine | 1966 |